Moorestown, New Jersey, United States
BiotechVortex™
Vortexes are powerful and transformational centers of energy
The BiotechVortex™ section of this site was created when I started seeing an increase in partnerships, mergers, and co-operative agreements, in both the biotech and medtech sectors. Here we will highlight these partnerships/agreements/mergers, even when no specific products are identified.
BiotechVORTEX - First Group Page
BiotechVortex™ - Second Group Page
BiotechVortex™
Gilead and Vir Biotechnology Establish Clinical Collaboration
Lilly and Merus NV Announce Collaboration
Lilly and Merus NV Announce Collaboration
Gilead and Vir Biotechnology Establish Clinical Collaboration
Lilly and Merus NV Announce Collaboration
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
January 19, 2021 Download PDF
INDIANAPOLIS and UTRECHT, The Netherlands, Jan. 19, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a clinical-stage oncology company developing multi-specific antibodies, today announced a research collaboration and exclusive license agreement that will leverage Merus' proprietary Biclonics® platform along with the scientific and rational drug design expertise of Loxo Oncology at Lilly to research and develop up to three CD3-engaging T-cell re-directing bispecific antibody therapies.
For additional information, please visit Merus' website, www.merus.nl and https://twitter.com/MerusNV.
To learn more about Lilly, please visit us at www.lilly.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-and-merus-nv-announce-collaboration-to-discover-novel-t-cell-re-directing-bispecific-antibodies-301210513.html
Our Pipeline
The product candidates in the Merus pipeline are based on the Multiclonics® format (full length human IgG antibodies). Our strategy employs the unique attributes of our proprietary bispecific antibodies and our patented screening technologies to engage and harness the power of the immune system to target tumor cells.
https://seekingalpha.com/symbol/LLY
Gilead and Vir Biotechnology Establish Clinical Collaboration
Gilead and Vir Biotechnology Establish Clinical Collaboration
Gilead and Vir Biotechnology Establish Clinical Collaboration
January 12, 2021
Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus
-- First Phase 2 Clinical Trial to Combine Immunomodulation and Antigen Suppression Approaches in HBV Cure Research --
FOSTER CITY, Calif. & SAN FRANCISCO--(BUSINESS WIRE)-- Gilead Sciences, Inc. (NASDAQ: GILD) and Vir Biotechnology, Inc. (NASDAQ: VIR) today announced that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing a functional cure for chronic hepatitis B virus (HBV).
Gilead and Vir Biotechnology Establish Clinical Collaboration
The companies plan to initiate a Phase 2 trial evaluating combination therapy for both treatment-experienced and treatment-naïve people living with HBV. The multi-arm trial will evaluate different combinations of selgantolimod, Gilead’s investigational TLR-8 agonist; VIR-2218, Vir’s investigational small interfering ribonucleic acid (siRNA); and a commercially-sourced, marketed PD-1 antagonist. People in the trial with HBV treatment experience may also receive Gilead’s Vemlidy® (tenofovir alafenamide fumarate, TAF). The primary outcome of the study will be the proportion of patients achieving a functional cure, defined as an off-therapy loss of hepatitis B surface antigen (HBsAg) and HBV DNA from the serum.
Both companies retain full rights to their individual product candidates and will discuss the potential path forward for any future combination studies based on the outcome of the Phase 2 trial.
VEMLIDY
INDICATION
VEMLIDY is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease.
Please click here to see full Prescribing Information for VEMLIDY, including BOXED WARNING.
Please see Important Facts about VEMLIDY, including important warnings.
For more information, please visit www.vir.bio.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
Gilead and Vir Biotechnology Establish Clinical Collaboration to Explore Combination Strategies for Functional Cure for Chronic Hepatitis B Virus
Tue January 12, 2021 8:00 AM|GlobeNewswire|About: GILD, VIR
– First Phase 2 clinical trial to combine immunomodulation and antigen suppression approaches in HBV cure research –
FOSTER CITY, Calif. and SAN FRANCISCO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Gilead Sciences, Inc. (GILD) and Vir Biotechnology, Inc. (VIR) today announced that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing a functional cure for chronic hepatitis B virus (HBV).
Gilead and VIR Biotechnology tie up in chronic hepatitis B virus cure setting
Jan. 12, 2021 8:12 AM ET Gilead Sciences, Inc. (GILD) By: Aakash Babu, SA News Editor1 Comment
- Gilead Sciences (NASDAQ:GILD) and Vir Biotechnology (NASDAQ:VIR) announces that the companies have entered into a clinical collaboration to evaluate novel therapeutic combination strategies aimed at developing a functional cure for chronic hepatitis B virus (HBV).
https://seekingalpha.com/symbol/GILD
https://seekingalpha.com/symbol/VIR
tislelizumab
Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health
Gilead and Vir Biotechnology Establish Clinical Collaboration
Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene
Jan 11, 2021
- Agreement expands Novartis Oncology portfolio, adding late-stage PD-1 for monotherapy and potential proprietary PD-1 combinations, driving mid- and long-term growth
- Novartis secures development and commercialization rights in North America, Europe, and Japan
- Accelerates Novartis immuno-oncology combination strategy with multiple potential tislelizumab plus Novartis therapy combinations
- Tislelizumab already approved for patients with classical Hodgkin’s lymphoma and metastatic urothelial carcinoma in China; 15 registration-enabling clinical trials under way in non-small cell lung cancer (NSCLC) and other solid tumors
Basel, January 11, 2021 — Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene, Ltd. in major markets outside of China, accelerating the potential for Novartis to enter the large and growing checkpoint inhibitor field. Tislelizumab is an anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells.
tislelizumab
Tislelizumab is approved by the China National Medical Products Administration (NMPA) as a treatment for certain patients with classical Hodgkin’s lymphoma and metastatic urothelial carcinoma. In addition, BeiGene has filed three supplemental new drug applications for tislelizumab in China for first-line treatment of patients with advanced squamous NSCLC in combination with chemotherapy, first-line treatment of patients with advanced non-squamous NSCLC in combination with chemotherapy, and previously treated unresectable HCC.
Find out more at https://www.novartis.com.
BeiGene Announces Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab
Mon January 11, 2021 4:30 PM|Business Wire|About: BGNE
Novartis to co-develop and commercialize tislelizumab in North America, Japan, EU, and six other European countries
BeiGene (BGNE) to receive $650 million upfront payment and is eligible to receive up to $1.55 billion in potential regulatory and sales milestone payments plus royalties on product sales
BeiGene has the option to co-detail tislelizumab in North America
Both parties have freedom to conduct combination trials globally
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)-- BeiGene, Ltd.
https://seekingalpha.com/symbol/BGNE
https://seekingalpha.com/symbol/NVS
BeiGene, Novartis in Pact to develop tislelizumab for cancer settings
Jan. 11, 2021 4:47 PM ET BeiGene, Ltd. (BGNE)
By: Vandana Singh, SA News Editor
- BeiGene (NASDAQ:BGNE) has announced a collaboration and license agreement with Novartis Pharma (NYSE:NVS) for the development, manufacture and commercialization of BeiGene’s anti-PD-1 antibody tislelizumab. https://seekingalpha.com/news/3650509-beigene-novartis-in-pact-to-develop-tislelizumab-for-cancer-settings
https://www.beigene.com/science-and-product-portfolio/pipeline/tislelizumab
Biogen, Genentech team up for a new neurodegenerative biotech
Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health
Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health
Biogen, Genentech team up for a new neurodegenerative biotech
Jan. 11, 2021 12:40 PM ET Roche Holding AG (RHHBY) By: Vandana Singh, SA News Editor
- Atalanta Therapeutics launches today with a Series A financing exclusively by F-Prime Capital.
Atalanta Therapeutics Launches With $110 Million to Pioneer RNAi Therapeutics for Neurodegenerative Diseases
Mon January 11, 2021 6:00 AM|Business Wire|About: BIIB, JNP
- Announces strategic collaborations with Biogen, Genentech to develop RNAi therapeutics for neurodegenerative diseases -
- Founders are world-leading experts in RNA interference, including Nobel (NLCI) laureate Craig Mello -
- Company has assembled a first-class management team of industry veterans helmed by CEO Alicia Secor -
BOSTON--(BUSINESS WIRE)-- Atalanta Therapeutics,
Preclinical research published in Nature Biotechnology has shown that branched siRNA can achieve unparalleled distribution in the CNS, including deep brain structures, and prolonged duration of effect.
For more information, visit www.atalantatx.com
F-Prime is headquartered in Cambridge, MA, with offices in London, UK and San Francisco, CA. For more information, please visit fprimecapital.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005327/en/
Biogen, Genentech and F-Prime power new neurodegenerative biotech to $110M unveiling
by Nick Paul Taylor | Jan 11, 2021 9:15am
https://seekingalpha.com/symbol/BIIB
https://seekingalpha.com/symbol/RHHBY
Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health
Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health
Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health
BIOGEN TO LAUNCH PIONEERING STUDY TO DEVELOP DIGITAL BIOMARKERS OF COGNITIVE HEALTH USING APPLE WATCH AND IPHONE
January 11, 2021 at 7:30 AM EST
- The study aims to identify digital biomarkers to help monitor cognitive performance and health including potentially detecting mild cognitive impairment, an early indicator of certain forms of dementia such as Alzheimer’s disease
- Cognitive health — the ability to think clearly, to learn and to remember — is an indicator of brain health and important to performing daily activities
CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced a new virtual research study, in collaboration with Apple, to investigate the role Apple Watch and iPhone could play in monitoring cognitive performance and screening for decline in cognitive health including mild cognitive impairment (MCI).
information that may be important to investors on our website at www.biogen.com.
“Working in collaboration with Biogen, we hope this study can help the medical community better understand a person's cognitive performance by simply having them engage with their Apple Watch and iPhone,” said Jeff Williams, Apple’s chief operating officer. “We’re looking forward to learning about the impact our technology can have in delivering better health outcomes through improved detection of declining cognitive health.”
https://www.biogen.com/en_us/home.html
Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone
Mon January 11, 2021 7:30 AM|GlobeNewswire|About: BIIB
Biogen, Apple collaborate to evaluate device role in digital biomarkers of cognitive health
Jan. 11, 2021 8:33 AM ET Biogen Inc. (BIIB) By: Vandana Singh, SA News Editor3 Comments
- Biogen (NASDAQ:BIIB)
https://www.biogen.com/en_us/pipeline.html
https://seekingalpha.com/symbol/BIIB
Chi-Med and Inmagene Announce Strategic Partnership
Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US
Sanofi to acquire Kymab, adding KY1005 to its pipeline
11 Jan 2021
Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases
Hong Kong, Shanghai, San Diego & Florham Park, NJ: Monday, January 11, 2021: Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) and Inmagene Biopharmaceuticals (“Inmagene”) today announce a strategic partnership to further develop four novel preclinical drug candidates discovered by Chi-Med for the potential treatment of multiple immunological diseases. Funded by Inmagene, the companies will work together to move the drug candidates towards investigational new drug (“IND”) submission. If successful, Inmagene will then move the drug candidates through global clinical development.
For additional information about Inmagene Biopharmaceuticals, please visit www.inmagenebio.com.
Chi-Med and Inmagene Announce Strategic Partnership to Develop and Commercialize Portfolio of Drug Candidates for Immunological Diseases
Sun January 10, 2021 8:00 PM|GlobeNewswire|About: HCM
HONG KONG, SHANGHAI, China, SAN DIEGO & FLORHAM PARK, N.J., Jan. 10, 2021 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (HCM) (“Chi-Med”) (Nasdaq/AIM: HCM) and Inmagene Biopharmaceuticals (“Inmagene”)
Chi-Med and Inmagene ink deal to develop candidates in immunological diseases
Jan. 11, 2021 12:54 AM ET Hutchison China MediTech Limited (HCM) By: Mamta Mayani, SA News Editor
- Hutchison China MediTech (NASDAQ:HCM)
Sanofi to acquire Kymab, adding KY1005 to its pipeline
Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US
Sanofi to acquire Kymab, adding KY1005 to its pipeline
January 11 2021
Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L
Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L
*Continues to build on Sanofi’s leading presence in immunology aligned with strategy to pursue best-in-class treatments in defined areas
PARIS and CAMBRIDGE, UK – January 11, 2021 – Sanofi and Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, have entered into an agreement under which Sanofi will acquire Kymab for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones.
For more information on Kymab please see http://www.kymab.com. Kymab and IntelliSelect are trademarks of Kymab Limited.
KY1005: Promising antibody for inflammatory disorders
In August 2020, Kymab announced that KY1005 met both primary endpoints in a Phase 2a trial studying moderate to severe atopic dermatitis patients whose disease is inadequately controlled with topical corticosteroids. KY1005 demonstrated a consistent treatment effect versus placebo across various key endpoints, including in the Eczema Area and Severity Index (EASI) and additional objective clinical measures.
“This acquisition aligns with our strategy of targeting fundamentally important disease pathways. We believe that OX40L, a key immune regulator, has the potential to rebalance the immune system without suppressing it, providing a promising new approach to treating a range of immune-mediated diseases,” said John Reed, M.D. Ph.D., Global Head of Research & Development at Sanofi.
Kymab’s pipeline also includes the oncology asset KY1044, an ICOS agonist monoclonal antibody, currently in early Phase 1/2 development as monotherapy and in combination with an anti-PD-L1. The acquisition also provides Sanofi with access to new antibody technologies and research capabilities.
Sanofi to buy Kymab for $1.45B
Jan. 11, 2021 3:30 AM ETSanofi (SNY)By: Mamta Mayani, SA News Editor
- Sanofi (NASDAQ:SNY) to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L.
https://seekingalpha.com/news/3650134-sanofi-to-buy-kymab-for-1_45b
https://seekingalpha.com/symbol/SNY
Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US
Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US
Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US
Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US and Develop National Surveillance Infrastructure
With support from the Centers for Disease Control and Prevention (CDC), Illumina and Helix have already identified more than 50 cases of the new variant in the US
SAN DIEGO--(BUSINESS WIRE)-- Illumina, Inc. (Nasdaq: ILMN) and Helix today announced a collaboration to augment national surveillance infrastructure in the US to track the emergence and prevalence of novel strains of SARS-CoV-2 with support from the CDC. The combination of Illumina’s sequencing technology and expertise and Helix’s national COVID-19 testing footprint will significantly expand the country’s existing surveillance efforts to detect and characterize emerging variants of SARS-CoV-2.
To learn more, visit www.illumina.com
https://seekingalpha.com/symbol/ILMN
Learn more at www.helix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210105006007/en/
Illumina gets CDC backing to track emergence of new COVID-19 strains
Jan. 09, 2021 1:55 PM ETIllumina, Inc. (ILMN)By: Dulan Lokuwithana, SA News Editor
Blacksmith Medicines launches with seed funding and a research collaboration with Lilly
ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology
Illumina and Helix Collaborate to Assess Prevalence of New SARS-CoV-2 UK Variant (B.1.1.7) in the US
Blacksmith Medicines launches with seed funding and a research collaboration with Lilly
-Blacksmith Medicines, a spin-out of Forge Therapeutics, is pioneering a novel metalloenzyme chemistry platform to create new immuno-oncology and inflammation medicines –
– Research collaboration combines Blacksmith’s innovative chemistry platform with Lilly’s research and development expertise for novel human metalloenzyme-targeted medicines; total potential deal value up to approximately $300M –
SAN DIEGO, California, January 8, 2021 – Blacksmith Medicines, Inc. (Blacksmith), a biotechnology company focused on creating novel medicines for immuno-oncology and inflammatory diseases by targeting human metalloenzymes, announced today that it has secured seed funding and has entered into a research collaboration with Eli Lilly and Company (Lilly). Lilly joins existing Blacksmith investors Evotec A.G., MP Healthcare Partners, MagnaSci Ventures, and Alexandria Venture Investments. Blacksmith is a spin-out of Forge Therapeutics, a leading antibiotic discovery company discovering therapies to combat the rise of drug resistance.
For further information, please visit the company’s website at www.BlacksmithMedicines.com
Blacksmith Medicines has developed a purpose-built platform focused on the discovery and development of small molecule inhibitors of metal-dependent enzymes. Over 30% of known enzymes are metalloenzymes, covering all major enzyme classes: oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. Metal ions, including magnesium, zinc, iron, manganese and copper are the essential ingredient in these metalloenzymes.
https://blacksmithmedicines.com/technology/
https://blacksmithmedicines.com/
Eli Lilly collaborates with Blacksmith Medicines in a deal worth $300M
Jan. 08, 2021 8:43 AM ET Eli Lilly and Company (LLY) By: Dulan Lokuwithana, SA News Editor1 Comment
https://seekingalpha.com/news/3649921-eli-lilly-collaborates-blacksmith-medicines-in-deal-worth-300m
Blacksmith Medicines Launches With Seed Funding and a Research Collaboration With Lilly
-Blacksmith Medicines, a spin-out of Forge Therapeutics, is pioneering a novel metalloenzyme chemistry platform to create new immuno-oncology and inflammation medicines -
- Research collaboration combines Blacksmith's innovative chemistry platform with Lilly's research and development expertise for novel human metalloenzyme-targeted medicines; total potential deal value up to approximately $300M -
https://seekingalpha.com/symbol/LLY
ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology
ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology
ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology
ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology
Los Angeles, CA, USA, January 7, 2021 – ImaginAb Inc., a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. (NYSE: PFE) to supply 89Zr CD8 Immuno-PET agent, which can be used to image CD8 T cells in cancer patients.
For more information about ImaginAb’s pipeline and technology, visit www.imaginab.com.
ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology
Thu January 7, 2021 3:00 AM|PR Newswire|About: PFE
LOS ANGELES, Jan. 7, 2021 /PRNewswire/ -- ImaginAb Inc., a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. (PFE) to supply 89Zr CD8 Immuno-PET agent, which can be used to image CD8 T cells in cancer patients.
View original content to download multimedia:http://www.prnewswire.com/news-releases/imaginab-announces-license-and-supply-agreement-with-pfizer-for-cd8-immunopet-technology-301202156.html
https://seekingalpha.com/symbol/PFE
ImaginAb inks supply deal with Pfizer for CD8 ImmunoPET technology in Cancer
Jan. 07, 2021 3:29 AM ETPfizer Inc. (PFE)By: Mamta Mayani, SA News Editor
PerkinElmer to Acquire Oxford Immunotec Global PLC
ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology
ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology
Home / Investors / News releases News release details PerkinElmer to Acquire Oxford Immunotec Global PLC
PerkinElmer to Acquire Oxford Immunotec Global PLC
January 7, 2021 at 7:00 AM ESTPDF Version
- PerkinElmer to acquire Oxford Immunotec for USD 22.00 per share in cash
- Transaction expected to be completed in the first half of 2021
WALTHAM, Mass. & LONDON--(BUSINESS WIRE)--Jan. 7, 2021-- PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) and Oxford Immunotec Global PLC (NASDAQ: OXFD) ("Oxford Immunotec" or the “Company”) are pleased to announce they have reached an agreement on terms under which PerkinElmer will acquire Oxford Immunotec (the “Acquisition”). It is intended that the Acquisition will be implemented by means of a U.K. High Court of Justice-sanctioned scheme of arrangement under Part 26 of the U.K. Companies Act 2006 between Oxford Immunotec and its shareholders (the “Scheme”).
Additional information can be found at www.OxfordImmunotec.com.
Product Pipeline
Our Focus
Our research and development activities focus on developing proprietary tests for the management of immune-regulated conditions. Our current focus is on four key areas: chronic infections, transplantation, autoimmune and inflammatory disease, and immune-oncology.
http://www.oxfordimmunotec.com/north-america/science/product-pipeline/
http://www.oxfordimmunotec.com/north-america/
PerkinElmer to acquire Oxford Immunotec for $591M
Today, 7:14 AM
https://seekingalpha.com/symbol/PKI
BiotechVortex™
Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact
Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact
Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact
January 06, 2021
Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors
SANTA MONICA, Calif. & OXFORD, England & SAN JOSE, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), and Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-drug conjugate (ADC)-based therapies, announced that the companies have entered into a research collaboration to evaluate five novel targets for a number of hematologic and solid tumor indications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210106005129/en/
For more information on Oxford BioTherapeutics, please visit www.oxfordbiotherapeutics.com.
For more information on Kite, please visit www.kitepharma.com.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors
Wed January 6, 2021 8:00 AM| Business Wire| About: GILD
SANTA MONICA, Calif. & OXFORD, England & SAN JOSE, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (Nasdaq: GILD), and Oxford BioTherapeutics Ltd. (OBT)
https://seekingalpha.com/symbol/GILD
Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact
Jan. 06, 2021 2:24 PM ET Gilead Sciences, Inc. (GILD)By: Vandana Singh, SA News Editor2 Comments
- Kite, a Gilead Company (GILD +3.1%) and Oxford BioTherapeutics have entered into a research collaboration to evaluate five targets for a number of hematologic and solid tumor indications, using latter's OGAP target discovery platform.
https://seekingalpha.com/news/3649376-gileads-kite-oxford-biotherapeutics-ink-immuno-oncology-pact
Biogen inks deal for ophthalmic gene therapy development
Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact
Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact
ViGeneron signs global collaboration agreement for ophthalmic gene therapy development
Tue January 5, 2021 2:00 AM|GlobeNewswire|About: BIIB
- Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target
- The companies will use ViGeneron’s proprietary vgAAV technology to efficiently transduce target cells via intravitreal injections
MUNICH, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) -- ViGeneron GmbH, a gene therapy company, today announced a global collaboration and licensing agreement with Biogen Inc. (BIIB) (Nasdaq: BIIB, Cambridge, Mass., USA)
For further information, please visit www.vigeneron.com.
https://seekingalpha.com/symbol/BIIB
Pipeline
https://www.biogen.com/en_us/pipeline.html
Biogen inks deal for ophthalmic gene therapy development
Jan. 05, 2021 2:39 AM ET Biogen Inc. (BIIB)
By: Mamta Mayani, SA News Editor4 Comments
https://seekingalpha.com/news/3648630-biogen-inks-deal-for-ophthalmic-gene-therapy-development
Zai Lab and Cullinan Oncology Announce Strategic Collaboration
Gilead's Kite, Oxford BioTherapeutics ink immuno-oncology pact
A2 Biotherapeutics Enters Into Collaboration Agreement With Merck
Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China
Mon December 28, 2020 7:30 AM|GlobeNewswire|About: ZLAB
- Zai Lab (ZLAB) to lead development and commercialization of CLN-081 in Greater China
- Cullinan will receive $20 million upfront, up to $211 million in future milestones, and royalties
- Zai Lab to join ongoing global trial for CLN-081
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited, an innovative commercial-stage biopharmaceutical company, and Cullinan Oncology
About CLN-081
CLN-081 is an orally available, small-molecule, next-generation, irreversible EGFR inhibitor designed to selectively target cells expressing mutant EGFR variants. CLN-081 is currently in a Phase 1/2a dose escalation and expansion trial evaluating oral, twice-daily administration of various doses in patients with NSCLC harboring EGFR Ex20ins mutations who have had at least one prior treatment with platinum-based chemotherapy or another approved standard therapy.
For additional information about the company, please visit www.zailaboratory.com
For additional information, please visit www.cullinanoncology.com.
https://seekingalpha.com/symbol/CGEM
https://www.cullinanoncology.com/
https://seekingalpha.com/symbol/ZLAB
Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China
December 28, 2020 at 7:30 AM ESTPDF Version
- Zai Lab to lead development and commercialization of CLN-081 in Greater China
- Cullinan will receive $20 million upfront, up to $211 million in future milestones, and royalties
- Zai Lab to join ongoing global trial for CLN-081
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and Cullinan Oncology, a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, today announced an exclusive license agreement for the development, manufacturing and commercialization of CLN-081 in Greater China.
A2 Biotherapeutics Enters Into Collaboration Agreement With Merck
BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER
A2 Biotherapeutics Enters Into Collaboration Agreement With Merck
A2 Biotherapeutics Enters Into Collaboration Agreement With Merck To Develop Allogeneic Cell Therapy For Solid Tumor Cancers
Wed December 23, 2020 10:07 AM|PR NewswirePR Newswire
AGOURA HILLS, Calif., Dec. 23, 2020 /PRNewswire/ -- A2 Biotherapeutics (www.a2bio.com)
https://www.a2bio.com/our-science
For more information, visit www.a2bio.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/a2-biotherapeutics-enters-into-collaboration-agreement-with-merck-to-develop-allogeneic-cell-therapy-for-solid-tumor-cancers-301197998.html
SOURCE A2 Biotherapeutics
https://seekingalpha.com/symbol/MRK
Merck, A2 Bio in development pact for allogeneic cell therapy candidates for cancer
Dec. 23, 2020 1:08 PM ETMerck & Co., Inc. (MRK)By: Vandana Singh, SA News Editor
BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER
BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER
BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER
BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER
Dec 22, 2020 PDF Version
WHIPPANY, N.J. & SAN FRANCISCO--(BUSINESS WIRE)--Dec. 22, 2020--
Bayer and Veracyte (Nasdaq: VCYT) today announced a new collaboration to advance the Precision Oncology Patient Identification Program in thyroid cancer. Through the program, Bayer will offer testing with Veracyte’s Afirma Xpression Atlas (XA) to identify underlying genomic drivers, including NTRK gene fusions, within patients’ tumors. The program will focus on patients with advanced or metastatic thyroid cancer that is radioactive iodine refractory (RAIR) who may potentially benefit from biomarker-driven therapies.
For more information, go to www.bayer.us.
For more information, please visit www.veracyte.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201222005138/en/
Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer
Tue December 22, 2020 8:15 AM|Business Wire|About: VCYT
WHIPPANY, N.J. & SAN FRANCISCO--(BUSINESS WIRE)-- Bayer and Veracyte (VCYT) (Nasdaq: VCYT)
https://seekingalpha.com/symbol/VCYT
https://seekingalpha.com/symbol/BAYZF
Veracyte and Bayer collaborate in precision oncology;
Dec. 22, 2020 11:34 AM ET
Veracyte, Inc. (VCYT)By: Dulan Lokuwithana,
SA News Editor
Aurinia inks deal for voclosporin in Europe and Japan with Otsuka Pharma
BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER
BAYER AND VERACYTE ANNOUNCE PRECISION ONCOLOGY COLLABORATION IN THYROID CANCER
Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
DOWNLOAD AS PDFDECEMBER 17, 2020
- Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and reimbursement milestone payments -
- Agreement includes royalties of up to 20 percent on net sales payable to Aurinia -
VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of oral voclosporin for the treatment of Lupus Nephritis (LN) in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine.
About Voclosporin
Voclosporin is a novel therapy in development for patients with LN, an inflammation of the kidney which is one of the most serious complications of the autoimmune disease SLE. If left untreated, LN can lead to irreversible kidney damage, kidney failure or even death. Through an extensive clinical program, voclosporin has demonstrated superiority to the standard-of-care for LN.
Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
Thu December 17, 2020 4:00 AM|Business Wire|About: AUPH
- Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and reimbursement milestone payments -
- Agreement includes royalties of up to 20 percent on net sales payable to Aurinia -
VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (AUPH)
Learn more about Otsuka Pharmaceutical Company on its global website at https://www.otsuka.co.jp/en.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005216/en/
https://www.auriniapharma.com/
https://seekingalpha.com/symbol/AUPH
Lilly Announces Agreement to Acquire Prevail Therapeutics
ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma
Lilly Announces Agreement to Acquire Prevail Therapeutics
Lilly Announces Agreement to Acquire Prevail Therapeutics
December 15, 2020Download PDFAcquisition will establish a gene therapy program at Lilly, anchored by Prevail's portfolio of neuroscience assets, and will broaden Lilly's commitment to use novel modalities to attempt to address otherwise fatal genetic forms of neurodegenerative disease
INDIANAPOLIS and NEW YORK, Dec. 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) today announced a definitive agreement for Lilly to acquire Prevail for $22.50 per share in cash (or an aggregate of approximately $880 million) payable at closing plus one non-tradable contingent value right ("CVR") worth up to $4.00 per share in cash (or an aggregate of approximately $160 million), for a total consideration of up to $26.50 per share in cash (or an aggregate of approximately $1.040 billion). The CVR is payable (subject to certain terms and conditions) upon the first regulatory approval of a product from Prevail's pipeline as set forth in more detail below. Prevail is a biotechnology company developing potentially disease-modifying AAV9-based gene therapies for patients with neurodegenerative diseases.
To learn more about Lilly, please visit us at www.lilly.com.
https://www.prevailtherapeutics.com/our-science/#overview
https://seekingalpha.com/symbol/LLY
Veracyte broadens the collaboration with JNJ
ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma
Lilly Announces Agreement to Acquire Prevail Therapeutics
VERACYTE ANNOUNCES EXPANSION OF COLLABORATION WITH THE LUNG CANCER INITIATIVE AT JOHNSON & JOHNSON<
Dec 15, 2020 PDF Version
Collaboration to Focus on 9,000-Patient Clinical Trial for Development of Future Lung Cancer Early-Detection Tests
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 15, 2020-- Veracyte, Inc. (Nasdaq: VCYT) today announced it has expanded its long-term strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson1. The collaboration will include a focus on the NOBLE trial, a 9,000-patient, prospective, multicenter clinical study designed to distinguish genomic and other differences in lung cancer development and progression among patients with lung nodules detected by CT imaging.
Veracyte broadens the collaboration with JNJ in early cancer detection
Dec. 15, 2020 9:49 AM ET Veracyte, Inc. (VCYT)By: Dulan Lokuwithana, SA News Editor
https://seekingalpha.com/news/3644460-veracyte-broadens-collaboration-jnj-in-early-cancer-dete
https://seekingalpha.com/symbol/VCYT
https://seekingalpha.com/symbol/JNJ
For more information, please visit www.veracyte.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201215005345/en/
PIPELINE
Reducing Unnecessary Surgeries and Informing Treatment Decisions in in cancer and other disease
https://www.veracyte.com/our-products/pipeline
ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma
ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma
ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma
ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater China and Singapore
DECEMBER, 14, 2020
- Hillhouse-backed Overland Pharmaceuticals to initially contribute $50 million to fund operations and development
LAUSANNE, Switzerland & SHANGHAI & BOSTON--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE:ADCT) and Overland Pharmaceuticals, a fully integrated biopharmaceutical company backed by Hillhouse Capital, today announced that they have jointly formed a new company, Overland ADCT BioPharma (CY) Limited, to develop and commercialize four of ADC Therapeutics’ antibody drug conjugate (ADC) product candidates for difficult-to-treat hematologic and solid tumors – loncastuximab tesirine (Lonca), ADCT-601, ADCT-602 and ADCT-901 – in greater China and Singapore. Overland Pharmaceuticals has invested $50 million in Overland ADCT BioPharma to fund operations, including development plans for approval of Lonca for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in the licensed territory.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201214005195/en/
For more information, please visit https://adctherapeutics.com/
https://seekingalpha.com/symbol/ADCT
https://www.overlandpharma.com/
OUR PIPELINE
https://www.overlandpharma.com/our-pipeline/
AstraZeneca buying Alexion in $39B cash and stock deal
Thermo Fisher Scientific Expands Global Footprint Drug Product Development& Commercial Manufacturing
ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma
AstraZeneca Agrees to Buy Alexion for $39 Billion
The deal would bolster the British drug giant’s footprint in rare diseases
By Jenny Strasburg and Joseph Walker
Updated Dec. 12, 2020 12:27 pm ET
LONDON— AstraZeneca AZN 0.71% PLC said it agreed to buy Boston-based Alexion Pharmaceuticals Inc. ALXN 1.78% for $39 billion in cash and stock, a move that would bolster the British drug giant’s footprint in rare diseases.
AstraZeneca to acquire Alexion bulking up rare disease portfolio
Dec. 12, 2020 11:52 AM ET
AstraZeneca PLC (AZN) By: Dulan Lokuwithana, SA News Editor
https://seekingalpha.com/news/3643893-astrazeneca-to-acquire-alexion-bulking-up-rare-disease-portfolio
https://seekingalpha.com/symbol/AZN
https://seekingalpha.com/symbol/ALXN
https://alexion.com/our-research/pipeline
Accelerating AstraZeneca’s strategic and financial development AstraZeneca to acquire Alexion This webinar and conference call for investors and analysts is being recorded 12 December 2020
https://www.astrazeneca.com/content/dam/az/PDF/2020/20201212_Call_Alxn_Cmb_prsn.pdf?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link
Gilead Sciences to Acquire MYR GmbH Thu December 10, 2020 8:00 AM|Business Wire|About: GILD
Thermo Fisher Scientific Expands Global Footprint Drug Product Development& Commercial Manufacturing
Thermo Fisher Scientific Expands Global Footprint Drug Product Development& Commercial Manufacturing
December 10, 2020
Gilead Sciences to Acquire MYR GmbH
– Gilead to Acquire Hepcludex™, a First-in-Class Entry Inhibitor, for Treatment of Chronic Hepatitis Delta Virus (HDV), Adding Immediate Revenue After Closing of Transaction –
– Hepcludex Was Conditionally Approved in Europe in July 2020 Based on Phase 2 Data and Submission for Accelerated Approval in United States is Anticipated in Second Half of 2021 –
– Acquisition Builds on Gilead’s Strength as a Global Leader in Virology and Liver Diseases with Addition of First Marketed Product for Treatment of HDV –
FOSTER CITY, Calif. & BAD HOMBURG, Germany--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and MYR GmbH, a German biotechnology company f
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201210005315/en/
Additional information about the agreement can be found at Gilead’s Investors page at http://investors.gilead.com.
For more information on MYR, please visit the company's website at www.myr-pharma.com.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
Gilead Sciences to Acquire MYR GmbH
Thu December 10, 2020 8:00 AM|Business Wire|About: GILD
https://seekingalpha.com/pr/18117705-gilead-sciences-to-acquire-myr-gmbh
https://seekingalpha.com/symbol/GILD
Thermo Fisher Scientific Expands Global Footprint Drug Product Development& Commercial Manufacturing
Thermo Fisher Scientific Expands Global Footprint Drug Product Development& Commercial Manufacturing
Thermo Fisher Scientific Expands Global Footprint Drug Product Development& Commercial Manufacturing
Thermo Fisher Scientific Further Expands Global Footprint for Drug Product Development and Commercial Manufacturing
WALTHAM, Mass., Dec. 9, 2020 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced it will further expand its footprint in North America and Europe for sterile drug product development and commercial manufacturing of critical medicines, therapies and vaccines.
https://corporate.thermofisher.com/en/home.html
https://www.thermofisher.com/us/en/home.html
Thermo Fisher Scientific Further Expands Global Footprint for Drug Product Development and Commercial Manufacturing
Wed December 9, 2020 8:00 AM|PR Newswire
WALTHAM, Mass., Dec. 9, 2020 /PRNewswire/ -- Thermo Fisher Scientific, the world leader in serving science, today announced it will further expand its footprint in North America and Europe for sterile drug product development and commercial manufacturing of critical medicines, therapies and vaccines.
For more information, please visit www.thermofisher.com.
https://seekingalpha.com/symbol/TMO
Thermo Fisher Scientific and Innoforce Partner to Establish Biologics and Steriles Drug Manufacturing Facility in China
Fri November 6, 2020 6:00 AM|PR Newswire|About: TMO
For more information, please visit www.innoforcepharma.com.
BiotechVortex™
中国生物制药向科兴中维注资5.15亿美元，持股15.03% 2020-12-7
Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel
Y-mAbs, inks distribution pact with Takeda for nerve cell cancer meds, Danyelza & omburtamab
Sino Biopharm secures room for future growth with US$515 million investment in Sinovac’s Covid-19 vaccine unit
Beijing-based generic drug maker buys 15 per cent stake in Sinovac Life Sciences, a unit of Nasdaq-listed pharmaceutical firm Sinovac Biotech
Deal comes ahead of major announcement from China to launch 600 million doses of Covid-19 vaccines for use this year
Eric Ng Published: 3:18pm, 7 Dec, 2020
http://www.sinobiopharm.com/index.html#/
中国生物制药向科兴中维注资5.15亿美元，持股15.03%
2020-12-7
2020年12月7日，中国生物制药发布公告称，连同其附属公司的全资附属公司香港俊领有限公司就以5.15亿美元向北京科兴中维生物技术有限公司（简称科兴中维）出资订立协议。于出资完成后，中国生物制药将于科兴中维的注册资本中拥有15.03%权益。科兴中维将于中国生物制药的财务报表中入账列为联营公司。
http://www.sinobiopharm.com/index.html#/news/newsdeatil?id=2630
Y-mAbs, inks distribution pact with Takeda for nerve cell cancer meds, Danyelza & omburtamab
Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel
Y-mAbs, inks distribution pact with Takeda for nerve cell cancer meds, Danyelza & omburtamab
- Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel
Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel
Dec 04, 2020PDF Version
NEW YORK and PETACH TIKVA, Israel, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB)
NEW YORK and PETACH TIKVA, Israel, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) (the “Company” or “Y-mAbs”) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment ofRead moreDec 04, 2020
Y-mAbs, inks distribution pact with Takeda for nerve cell cancer meds, Danyelza & omburtamab
Dec. 04, 2020 9:30 AM ETY-mAbs Therapeutics, Inc. (YMAB)By: Vandana Singh, SA News Editor
https://seekingalpha.com/symbol/YMAB
https://seekingalpha.com/symbol/TAK
About the Y-mAbs development pipeline of therapies
https://ymabs.com/research-development/pipeline/
Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel
Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel
Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel
Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology
Thu December 3, 2020 3:00 AM|PR Newswire
- Merck KGaA, Darmstadt, Germany and Artios will conduct collaborative research and Merck KGaA, Darmstadt, Germany shall have the right to opt into exclusive development and commercialization of compounds on up to 8 targets
- Artios to receive US$30 million in up-front and near-term payments, plus double-digit option fees and up to US$860 million total milestones per target
- Collaboration to leverage significant expertise and R&D resources of Merck KGaA, Darmstadt, Germany in the field of DNA Damage Response to identify and develop precision oncology medicines targeting nucleases
DARMSTADT, Germany, CAMBRIDGE, UK and NEW YORK, Dec. 3, 2020 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany, a leading science and technology company and Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, today announced a global three year strategic research collaboration to discover and develop multiple precision oncology drugs.
View original content:http://www.prnewswire.com/news-releases/merck-kgaa-darmstadt-germany-and-artios-pharma-announce-a-global-strategic-collaboration-on-novel-dna-damage-response-targets-in-oncology-301185247.html
https://seekingalpha.com/symbol/MKGAY
https://www.artiospharma.com/science/#pipeline
December 3, 2020
Bioengineered Antibody-Toxin Fusion Proteins- FastPharming® System
Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extract
Merck KGaA, Darmstadt, Germany and Artios Pharma Announce a Global Strategic Collaboration on Novel
iBio Selected to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins
Tue December 1, 2020 4:30 PM | Globe Newswire | About: IBIO
BRYAN, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (IBIO) (NYSEA:IBIO)
Bioengineered Antibody-Toxin Fusion Proteins
New line of attack against cancer
atbodies are differentiated by both their unique composition and novel mechanism of action, providing a new class of biologic as an innovative therapeutic solution for hard-to-treat and refractory cancer.
https://www.atbtherapeutics.com/atbody
under a Master Services Agreement with Belgium-based ATB Therapeutics (“atbtherapeutics”) to produce its bioengineered antibody-toxin fusion proteins using iBio’s FastPharming® System.
FastPharming® System
FastPharming®
Advantages of Plant Based Protein Production
https://www.ibioinc.com/technology/fastpharming
For more information, visit www.ibioinc.com.
https://seekingalpha.com/symbol/IBIO
For more information, visit www.atbtherapeutics.com.
BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years
Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extract
Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extract
BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years
Wed December 2, 2020 7:00 AM|PR Newswire|About: BDX
- Investment includes new manufacturing facility in Europe
FRANKLIN LAKES, N.J., Dec. 2, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company (BDX)) (NYSE: BDX)
The new manufacturing facility in Europe is expected to be operational by the end of 2023.
For more information on BD, please visit bd.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/bd-to-invest-1-2-billion-in-pre-fillable-syringe-manufacturing-capacity-over-next-four-years-301183330.html
12/02/2020
BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years
https://seekingalpha.com/symbol/BDX
Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extract
Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extract
Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extract
Tilray, Inc. and Hormosan Sign a Cooperation Agreement for the Promotion of Medical Cannabis Extracts in Germany
Wed December 2, 2020 8:00 AM|Business Wire|About: TLRY
BERLIN & FRANKFURT, Germany--(BUSINESS WIRE)-- Tilray, Inc. (TLRY) (“Tilray” or the “Company”) (Nasdaq: TLRY), a leading company in the manufacture, research and distribution of medical cannabis, announced that it has entered into a co-promotion agreement with Hormosan for its full-spectrum cannabis extracts in Germany effective 1 January 2021.
"With Hormosan we have gained a partner that has excellent expertise and contacts in the field of pain therapy and neurology and will thus significantly increase the visibility of Tilray's full-spectrum cannabis extracts in the future," explains Sascha Mielcarek, Managing Director Europe at Tilray. “This will give physicians and patients even better access to our medical cannabis extracts while supporting our goal of contributing to improved care for patients with medical cannabis."
View source version on businesswire.com: https://www.businesswire.com/news/home/20201202005128/en/
HORMOSANSeltene Erkrankungen
in der Neurologie
https://www.hormosan.com/seltene_erkrankungen.html
BERLIN & FRANKFURT, Germany --(BUSINESS WIRE)--Dec. 2, 2020-- Tilray, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY), a leading company in the manufacture, research and distribution of medical cannabis, announced that it has entered into a co-promotion agreement with Hormosan for its full-spectrum
December 2, 2020
https://seekingalpha.com/symbol/TLRY
Frontier Medicines and AbbVie Establish Global Partnership to Discover and Develop Novel Therapies
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Br
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Br
Frontier Medicines and AbbVie Establish Global Partnership to Discover and Develop Novel Therapies and E3 Degraders Against Difficult-to-Drug Targets
Wed December 2, 2020 8:00 AM|PR Newswire|About: ABBV
- Frontier eligible to receive up to $100 million in upfront and milestone payments within the first 12 months of collaboration
PR Newswire
NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Dec. 2, 2020 /PRNewswire/ -- AbbVie (ABBV), a research-based global biopharmaceutical company, and Frontier Medicines, Corp.,
For more information, visit www.frontiermeds.com
For more information about AbbVie, please visit us at www.abbvie.com.
https://seekingalpha.com/symbol/ABBV
Science
https://frontiermeds.com/science/#chemoproteomics
Dec 02, 2020
NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Dec. 2, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Frontier Medicines, Corp., a precision medicine company drugging challenging protein targets to develop breakthrough medicines that change the course of human diseases, today announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative small molecule therapeutics against high-interest, difficult-to-drug protein targets.
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Br
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Br
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Br
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders
Fri November 27, 2020 7:30 AM|Business Wire|About: BIIB, SAGE
- Biogen and Sage enter into an agreement to jointly develop and commercialize zuranolone and SAGE-324 in the U.S.
- Biogen to receive exclusive license to develop and commercialize zuranolone and SAGE-324 outside of the U.S., excluding rights to zuranolone in Japan, Taiwan and South Korea
- Sage Therapeutics (SAGE) to receive $1.525 billion in cash comprised of an upfront payment of $875 million and a $650 million equity investment as well as potential milestone payments, profit sharing and royalties
- Sage to host conference call Monday, November 30 at 8:00 a.m. ET
- Biogen to host conference call Monday, November 30 at 9:00 a.m. ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (BIIB) (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that they have executed a global collaboration and license agreement to jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), postpartum depression (PPD) and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201127005340/en/
Zuranolone is a next-generation positive allosteric modulator of the gamma-aminobutyric acid (GABAA) receptor. The GABAA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS), and contributes significantly to regulating CNS function. This mechanism of action is a novel approach that may enable a new class of antidepressants.
We routinely post information that may be important to investors on our website at www.biogen.com.
https://seekingalpha.com/symbol/BIIB
For more information, please visit www.sagerx.com.
https://seekingalpha.com/symbol/SAGE
https://www.sagerx.com/programs-research/pipeline/
November 27, 2020
BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Br
BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel
BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel Immunotherapies
Wed November 25, 2020 7:45 AM|GlobeNewswire|About: BNTX
- Long-term collaboration underpins BioNTech’s strategy to leverage Artificial Intelligence (AI) and Machine Learning (ML) technologies to support the discovery and development of novel immunotherapies based on InstaDeep’s DeepChainTM technology platform
- BioNTech (NTGN) and InstaDeep to establish a joint AI Innovation Lab to advance a portfolio of enterprise-wide digital initiatives in the areas of drug discovery and design, protein engineering, and operations
MAINZ, Germany and LONDON, United Kingdom, November 25, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech”) and InstaDeep Ltd
For more information, please visit www.BioNTech.de.
To learn more, please visit www.instadeep.com.
https://seekingalpha.com/symbol/BNTX
Research
InstaDeep’s in-house research team contributes to the latest advancements in AI – from the fundamentals of machine learning to robotics and deep reinforcement learning. Our published research has been presented at world-leading conferences such as NeurIPS 2018.
https://www.instadeep.com/research/
25 November 2020
BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation ..
Schrödinger Announces a Collaboration with Bristol Myers Squibb
Schrödinger Announces a Collaboration with Bristol Myers Squibb
BioNTech and InstaDeep Announce Strategic Collaboration and Form AI Innovation Lab to Develop Novel
Schrödinger Announces a Multi-Target Drug Discovery, Development, and Commercialization Collaboration with Bristol Myers Squibb
Mon November 23, 2020 6:30 AM|Business Wire|About: BMY, SDGR
Schrödinger to receive $55 million upfront; eligible to receive up to $2.7 billion in milestone payments plus royalties
NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced a discovery collaboration with Bristol Myers Squibb Company (NYSE: BMY) to discover, develop, and commercialize therapeutics in multiple disease areas.
To learn more, visit www.schrodinger.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201123005663/en/
https://seekingalpha.com/symbol/SDGR
https://seekingalpha.com/symbol/BMY
Schrödinger inks multi-target drug discovery deal with Bristol-Myers Squibb
https://www.schrodinger.com/pipeline
OneOncology Partners with Genentech
Schrödinger Announces a Collaboration with Bristol Myers Squibb
OneOncology Partners with Genentech
OneOncology Partners with Genentech to Bring Personalized Cancer Research to Patients at Community Oncology Sites
Mon November 23, 2020 6:15 AM|PR Newswire|About: RHHBY
MyTACTIC Precision Basket Trial is Scheduled to Launch in December 2020 at Community Oncology Centers Including OneOncology
PR Newswire
NASHVILLE, Tenn., Nov. 23, 2020 /PRNewswire/ -- OneOncology, the national partnership of independent oncology practices, and Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)
Genentech's new clinical trial -- Targeting Actionable Mutation Study in Cancer (MyTACTIC) -- aims to match patient populations with a targetable genomic alteration to a specific investigational agent.
View original content to download multimedia:http://www.prnewswire.com/news-releases/oneoncology-partners-with-genentech-to-bring-personalized-cancer-research-to-patients-at-community-oncology-sites-301178283.html
About OneOncology:
OneOncology is a national partnership of independent, community oncology practices working together to improve the lives of everyone living with cancer through a physician-led, data-driven, technology-powered and patient-centric model. OneOncology is comprised of leading community oncology practices representing over 475 providers practicing at nearly 175 sites of care across the United States.
https://seekingalpha.com/symbol/RHHBY
Merck to Acquire OncoImmune
Schrödinger Announces a Collaboration with Bristol Myers Squibb
OneOncology Partners with Genentech
Merck to Acquire OncoImmune
November 23, 2020 6:45 am EST
Acquisition adds to Merck’s suite of clinical programs in response to SARS-CoV-2/COVID-19
Merck will accelerate development of CD24Fc, a candidate for the treatment of patients with severe and critical COVID-19
KENILWORTH, N.J., & ROCKVILLE, Md.--(BUSINESS WIRE)-- Merck (NYSE: MRK)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201123005593/en/
Merck adds to suite of COVID-19 clinical programs through OncoImmune acquistion
Nov. 23, 2020 6:54 AM ETMerck & Co., Inc. (MRK)By: Gaurav Batavia, SA News Editor
https://seekingalpha.com/symbol/MRK
Visit www.oncoimmune.com.
BiotechVortex™
QIAGEN Collaborates with BioNTech on Companion Diagnostics Development
Lilly & Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes
Lilly & Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes
QIAGEN Collaborates with BioNTech on Companion Diagnostics Development for HPV-associated Squamous Cell Carcinoma of the Head and Neck
Wed November 18, 2020 4:05 PM|Business Wire|About: BNTX, QGEN
- QIAGEN and BioNTech (NTGN) to develop tissue-based therascreen® test covering a panel of HPV genotypes, paired with investigational treatment BNT113, to identify patients whose cancers are caused by HPV infections
- QIAGEN to pursue global regulatory approvals, including Premarket Approval from FDA for companion diagnostics
- Collaboration leverages QIAGEN´s global reach and market-leading position in companion diagnostics and HPV testing
HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)-- QIAGEN N.V. (QGEN)
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005908/en/
https://seekingalpha.com/symbol/QGEN
https://seekingalpha.com/symbol/BNTX
Lilly & Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes
Lilly & Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes
Lilly & Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes
Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes
Thu November 19, 2020 6:45 AM|PR Newswire|About: LLY
BURGDORF, Switzerland and INDIANAPOLIS, Nov. 19, 2020 /PRNewswire/ -- Eli Lilly and Company (LLY) and Ypsomed (YPHDF) (SWX: YPSN) For the latest updates, visit http://www.lillydiabetes.com/
Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes
Additional information is available under www.ypsomed.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/lilly-and-ypsomed-collaborate-to-advance-an-automated-insulin-delivery-system-for-people-with-diabetes-301176401.html
November 19, 2020
Tags | Product
BURGDORF, Switzerland and INDIANAPOLIS , Nov. 19, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Ypsomed (SWX: YPSN) announced today a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly 's connected diabetes solutions.
https://seekingalpha.com/symbol/LLY
Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in G
Lilly & Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes
Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in G
Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in Greater China
Thu November 19, 2020 7:00 AM|Business Wire|About: PFE
NEW YORK & SHANGHAI & PRINCETON, N.J.--(BUSINESS WIRE)-- Pfizer, Inc. (PFE) and LianBio
For more information, please visit lianbio.com.
We routinely post information that may be important to investors on our website at www.pfizer.com.cn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005290/en/
https://www.lianbio.com/pipeline/
https://seekingalpha.com/symbol/PFE
Ultragenyx to build gene therapy manufacturing facility
Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders
Pfizer and LianBio Announce Strategic Collaboration to Expand Development of Novel Therapeutics in G
Ultragenyx Announces Plans to Build Large-scale Gene Therapy Manufacturing Facility to Support Pipeline of Therapies for Rare Diseases
Mon November 9, 2020 8:05 AM|GlobeNewswire|About: RARE
State-of-the-art facility to be located in Bedford, Massachusetts
NOVATO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx to build gene therapy manufacturing facility
Nov. 9, 2020 9:27 AM ET|About: Ultragenyx Pharmaceutical... (RARE)|By: Vandana Singh, SA News Editor
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
https://seekingalpha.com/symbol/RARE
Novartis buys Vedere Bio for $280M
Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders
Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders
Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company
Thu October 29, 2020 2:15 AM|PR Newswire
$150 million upfront with the remainder in early regulatory and clinical milestones for a total of $280 million
Newly formed Vedere Bio II will leverage an ocular gene therapy toolbox to develop a new pipeline of novel vision restoration and vision preservation therapies
PR Newswire
CAMBRIDGE, Mass., Oct. 29, 2020 /PRNewswire/ -- Vedere Bio, Inc. (Vedere Bio), a stealth-stage company focused on advancing photoreceptor-protein-based optogenetic therapies that are delivered to the retina intravitreally to restore functional vision, announced today that it has been acquired by Novartis.
Novartis buys Vedere Bio for $280M
https://seekingalpha.com/news/3627953-novartis-buys-vedere-bio-for-280m
View original content to download multimedia:http://www.prnewswire.com/news-releases/novartis-acquires-vedere-bio-a-novel-optogenetics-aav-gene-therapy-company-301162269.html
SOURCE Vedere Bio, Inc.
https://seekingalpha.com/symbol/NVShttps://seekingalpha.com/symbol/NVS
Novartis acquires Vedere Bio, adding novel optogenetic gene therapy technology for treating blindness
Oct 29, 2020
- Acquisition expands the Novartis footprint in ophthalmology and enhances the company’s position as an AAV-based gene therapy powerhouse.
- Novartis gains two pre-clinical optogenetic AAV gene therapy programs and novel delivery technology for treating inherited retinal dystrophies and geographic atrophy.
- Inherited retinal dystrophies, including advanced retinitis pigmentosa, affect greater than 2 million patients worldwide, and geographic atrophy affects approximately 5 million patients worldwide.
Basel, October 29, 2020
Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders
Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders
Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders
insitro Announces Five-Year Discovery Collaboration with Bristol Myers Squibb to Discover and Develop Novel Treatments for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Wed October 28, 2020 7:00 AM|Business Wire|About: BMY
insitro to Receive $50 Million in Upfront Cash with Total Potential Deal Value Over $2.1 Billion
Collaboration to Advance Targets and Therapeutic Candidates
SAN FRANCISCO--(BUSINESS WIRE)-- insitro
For more information on insitro, please visit the company’s website at www.insitro.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201028005276/en/
Insitro inks five-year pact with Bristol-Myers for neurodegenerative disorders
Oct. 28, 2020 7:26 AM ET|About: Bristol-Myers Squibb Company (BMY)|By: Vandana Singh, SA News Editor
https://seekingalpha.com/symbol/BMY
Jazz Pharmaceuticals acquires SpringWorks Therapeutics' FAAH inhibitor program
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New G
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New G
Jazz Pharmaceuticals Acquires SpringWorks Therapeutics' FAAH Inhibitor Program
Mon October 26, 2020 7:30 AM|PR Newswire|About: JAZZ, SWTX
Strategically Expands Jazz's Mid-Stage Neuroscience Pipeline into a New Disease Area and Further Optimizes SpringWorks' Strategic Focus on Targeted Oncology
Jazz to Make Upfront Payment of $35 Million to SpringWorks with Potential Milestone Payments of Up to $375 Million
PR Newswire
DUBLIN and STAMFORD, Conn., Oct. 26, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) and SpringWorks Therapeutics, Inc. (SWTX)
For more information, please visit www.jazzpharmaceuticals.com
For more information, visit www.springworkstx.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-acquires-springworks-therapeutics-faah-inhibitor-program-301159303.html
https://www.springworkstx.com/pipeline/
https://www.jazzpharma.com/science/pipeline/
https://seekingalpha.com/symbol/JAZZ
https://seekingalpha.com/symbol/SWTX
October 26, 2020
Jazz Pharmaceuticals Acquires SpringWorks Therapeutics’ FAAH Inhibitor Program
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New G
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New G
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New G
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy
Fri October 23, 2020 8:00 AM|GlobeNewswire|About: RARE, SLDB
-Collaboration combines Solid’s differentiated microdystrophin construct and Ultragenyx’s HeLa PCL manufacturing platform for use with AAV8 and variants-
-Solid receives $40 million upfront via equity investment at a premium; up to $255 million in milestones plus royalty payments-
-Solid retains exclusive rights to all other uses of its microdystrophins, including its existing SGT-001 program-
NOVATO, Calif. and CAMBRIDGE, Mass., Oct. 23, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (RARE)
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
For more information, please visit www.solidbio.com.
https://seekingalpha.com/symbol/RARE
https://www.ultragenyx.com/pipeline/
Toggle Summary Oct 23, 2020Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New Gene Therapies for Duchenne Muscular Dystrophy
Ultragenyx and Solid Biosciences Announce Strategic Collaboration to Develop and Commercialize New G
Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines
Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwan
Mon October 12, 2020 4:05 PM|GlobeNewswire|About: ATNX
BUFFALO, N.Y., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Axis Therapeutics Limited, a joint venture between Athenex, Inc. (ATNX) and Xiangxue Life Sciences Limited (“XLifeSc”), focused on the research, development, and commercialization of T cell immunotherapy, today announced that it has entered into a research collaboration with PharmaEssentia Corporation (Taipei Exchange: 6446).
For more information, please visit: www.axistherapeutics.com.
For more information, please visit www.pharmaessentia.com .
For more information about XPH, visit www.xphcn.com.
For more information, please visit www.athenex.com.
https://seekingalpha.com/symbol/ATNX
Axis Therapeutics inks research pact with PharmaEssentia for cancer T-cell therapy
Oct. 12, 2020 4:20 PM ET|About: Athenex, Inc. (ATNX)|By: Vandana Singh, SA News Editor
Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines
Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines
Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines
Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines for Neurological Diseases, Including Amyotrophic Lateral Sclerosis
Tue October 6, 2020 10:00 AM|Business Wire|About: BIIB
Committed to expanding treatment for underserved genetic conditions, Scribe and Biogen to collaborate on the development of novel genetic medicines for neurodegeneration
ALAMEDA, Calif.--(BUSINESS WIRE)-- Scribe Therapeutics Inc., the company focused on engineering the most advanced platform for CRISPR-based genetic medicine, today announced a research collaboration with Biogen Inc. (BIIB) to develop and commercialize CRISPR-based therapies that address an underlying genetic cause of Amyotrophic Lateral Sclerosis (ALS).
To learn more about Scribe’s mission to rewrite the story of disease, visit www.scribetx.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005506/en/
Innovent Bio's expanded collaboration with Lilly for Tyvyt now effective
Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines
Innovent Bio's expanded collaboration with Lilly for Tyvyt now effective
Innovent Announces the Effectiveness of the Expanded Global Collaboration with Lilly on TYVYT® (sintilimab injection) Following the Expiration of HSR Act Waiting Period
Tue October 6, 2020 8:00 PM|PR Newswire|About: IVBIY
SAN FRANCISCO and SUZHOU, China, Oct. 6, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (IVBIY) ("Innovent") (HKEX: 01801)
For more information, please visit: www.innoventbio.com.
Innovent Bio's expanded collaboration with Lilly for Tyvyt now effective
Oct. 7, 2020 12:38 AM ET|About: Innovent Biologics, Inc. (IVBIY)|By: Mamta Mayani, SA News Editor
http://innoventbio.com/en/#/product/products
Takeda and Arrowhead Pharmaceuticals team up in rare liver disease
Scribe Therapeutics to Collaborate With Biogen to Develop CRISPR-based Genetic Medicines
Innovent Bio's expanded collaboration with Lilly for Tyvyt now effective
Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
Thu October 8, 2020 7:30 AM|Business Wire|About: ARWR, TAK
− Potential first-in-class therapy designed to treat the underlying cause of liver disease associated with AATD
− Arrowhead is eligible to receive up to $1.04B including an upfront payment of $300M and potential development, regulatory and commercial milestones up to $740M
− Investigational medicine ARO-AAT to be co-developed and co-commercialized in the United States by Takeda (TKPHF) and Arrowhead under a 50/50 profit-sharing structure
− Takeda receives exclusive license to commercialize ARO-AAT outside the U.S.
− Arrowhead will hold a conference call and webcast today, Oct. 8, at 8:30 a.m. ET
OSAKA, Japan & PASADENA, Calif.--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (ARWR)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201008005340/en/
For more information, visit https://www.takeda.com.
https://www.takeda.com/investors/
For more information, please visit www.arrowheadpharma.com
https://seekingalpha.com/symbol/ARWR
Pipeline
Novel Drugs to
Treat Intractable Diseases
https://arrowheadpharma.com/pipeline/
Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
October 8, 2020 Osaka, JAPAN, and Pasadena, CALIF.
- Potential first-in-class therapy designed to treat the underlying cause of liver disease associated with AATD
- Arrowhead is eligible to receive up to $1.04B including an upfront payment of $300M and potential development, regulatory and commercial milestones up to $740M
- Investigational medicine ARO-AAT to be co-developed and co-commercialized in the United States by Takeda and Arrowhead under a 50/50 profit-sharing structure
- Takeda receives exclusive license to commercialize ARO-AAT outside the U.S.
- Arrowhead will hold a conference call and webcast today, Oct. 8, at 8:30 a.m. ET
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR)
BiotechVortex™
Bristol Myers Squibb to acquire Myokardia for $13.1B in cash
CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China
CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China
Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash
Mon October 5, 2020 6:30 AM|Business Wire|About: BMY, MYOK
Mavacamten Is a Potential First-in-Class Medicine with Compelling Data in the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Mavacamten Will Be a Medium- and Long-Term Growth Driver Presenting a Significant Commercial Opportunity upon Approval
Promising Portfolio of Pipeline Candidates Strengthens and Extends Bristol Myers Squibb’s Leading Cardiovascular Franchise
Expected to be Accretive to Non-GAAP Earnings Starting in 2023
NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (MYOK)
For more information about Bristol Myers Squibb, visit us at BMS.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201005005381/en/
Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash
10/05/2020CATEGORY:
Mavacamten Is a Potential First-in-Class Medicine with Compelling Data in the Treatment of Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Mavacamten Will Be a Medium- and Long-Term Growth Driver Presenting a Significant Commercial Opportunity upon Approval
Promising Portfolio of Pipeline Candidates Strengthens and Extends Bristol Myers Squibb’s Leading Cardiovascular Franchise
Expected to be Accretive to Non-GAAP Earnings Starting in 2023
NEW YORK & BRISBANE, Calif.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire MyoKardia for $13.1 billion, or $225.00 per share in cash. The transaction was unanimously approved by both the Bristol Myers Squibb and MyoKardia Boards of Directors and is anticipated to close during the fourth quarter of 2020.
https://seekingalpha.com/symbol/MYOK
https://seekingalpha.com/symbol/BMY
CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China
CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China
CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China
CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China
Tue September 29, 2020 11:22 PM|Business Wire|About: LGND, PFE
- Pfizer (PFE) to invest $200 million in CStone shares and license CStone’s late-stage oncology asset sugemalimab (CS1001, PD-L1 antibody) in mainland China
- CStone to receive up to $280 million in milestone payments for sugemalimab, and additional royalties
- CStone and Pfizer to develop and commercialize additional late-stage oncology therapies in Greater China
SUZHOU, China--(BUSINESS WIRE)-- CStone Pharmaceuticals (CSPHF) (“CStone”, HKEX: 2616)] and Pfizer Investment Co. Ltd. ("Pfizer Investment") and Pfizer Corporation Hong Kong Limited ("Pfizer Hong Kong") (both of which are subsidiaries of Pfizer Inc.)
For more information about CStone, please visit: www.cstonepharma.com.
http://www.cstonepharma.com/en/
For more information, please visit www.pfizer.com.cn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200929006175/en/
https://seekingalpha.com/symbol/PFE
https://seekingalpha.com/symbol/CSPHF
CSTONE PHARMACEUTICALS - B (2616)
https://www.hkex.com.hk/Market-Data/Securities-Prices/Equities/Equities-Quote?sym=2616&sc_lang=en
Roche doubles down on promising inflammation field with Inflazome buy
CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China
Roche doubles down on promising inflammation field with Inflazome buy
Inflazome Announces Acquisition by Roche
Mon September 21, 2020 2:00 AM|Business Wire|About: RHHBY
- Inflazome is a pioneering inflammasome company developing orally available NLRP3 inflammasome inhibitors to address clinical unmet needs across a wide variety of inflammatory diseases
- Acquisition of Inflazome gives Roche (RHHBY) full rights to the Inflazome portfolio
- Activation of the NLRP3 inflammasome in the body is implicated in many diseases caused by chronic, uncontrolled inflammation
- Inflazome shareholders received €380 million upfront, and are eligible to receive additional milestone payments
DUBLIN & CAMBRIDGE, England--(BUSINESS WIRE)
View source version on businesswire.com: https://www.businesswire.com/news/home/20200920005066/en/
https://www.cell.com/fulltext/S0092-8674%2810%2900075-9
https://seekingalpha.com/symbol/RHHBY
Roche doubles down on promising inflammation field with Inflazome buy
Sep. 26, 2020 12:30 AM ET|About: Roche Holding AG (RHHBY)|By: Douglas W. House, SA News Editor
Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement
Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development
Roche doubles down on promising inflammation field with Inflazome buy
Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease
Wed September 23, 2020 2:00 AM|Business Wire|About: PFE
PARIS & NEW YORK--(BUSINESS WIRE)-- Vivet Therapeutics
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200922005790/en/
Please visit us on www.vivet-therapeutics.com
PFIZER SECURES EXCLUSIVE OPTION TO ACQUIRE GENE THERAPY COMPANY VIVET THERAPEUTICS
Pfizer and Vivet to collaborate on development of potential breakthrough therapy for Wilson disease
Pfizer acquires 15% ownership stake in Vivet
Paris, France and New York, US, March 20, 2019 – Vivet Therapeutics (“Vivet”),
https://seekingalpha.com/symbol/PFE
Pepinemab in Combination with KEYTRUDA
Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development
Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development
Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Thu September 17, 2020 8:00 AM|GlobeNewswire|About: VCNX
ROCHESTER, N.Y., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX)
Vaccinex partners with Merck in cancer
Sep. 17, 2020 8:31 AM ET|About: Vaccinex, Inc. (VCNX)|By: Mamta Mayani, SA News Editor .com/news/3614927-vaccinex-partners-merck-in-cancer
https://seekingalpha.com/news/3614927-vaccinex-partners-merck-in-cancer
http://www.vaccinex.com/pipeline/pepinemab-immuno-oncology/
https://seekingalpha.com/symbol/VCNX
Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
ROCHESTER, N.Y., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX)
Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development
Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development
Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development
Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development
Thu September 17, 2020 8:30 AM|Accesswire|About: DYAI
LIANYUNGANG, CHINA and JUPITER, FL / ACCESSWIRE / September 17, 2020 / Dyadic International, Inc. (DYAI) ("Dyadic" or the "Company") (NASDAQ:DYAI)
Please visit Dyadic's website at http://www.dyadic.com for additional information
please visit http://www.hrs.com.cn/index.html.
http://www.hrs.com.cn/index.html
Dyadic teams up with Jiangsu Hengrui for biologic drug development
Sep. 17, 2020 9:05 AM ET|About: Dyadic International, Inc. (DYAI)|By: Mamta Mayani, SA News Editor
https://seekingalpha.com/news/3614955-dyadic-teams-up-jiangsu-hengrui-for-biologic-drug-development
https://seekingalpha.com/symbol/DYAI
BiotechVortex™
Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies
Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies
Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies
Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies
Thu September 17, 2020 6:30 AM|PR Newswire|About: AMGN, LLYPR Newswire
INDIANAPOLIS and THOUSAND OAKS, Calif., Sept. 17, 2020 /PRNewswire/ -- Eli Lilly and Company (LLY) and Amgen (AMGN)
For more information, visit www.amgen.com
To learn more about Lilly, please visit us at lilly.com
https://seekingalpha.com/symbol/AMGN
https://seekingalpha.com/symbol/LLY
https://www.lilly.com/discovery/clinical-development-pipeline
Takeda Opens New R&D Cell Therapy Manufacturing Facility
Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies
Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies
Takeda Opens New R&D Cell Therapy Manufacturing Facility to Support Expansion of Next-Generation Clinical Programs
Tue September 15, 2020 7:30 AM|Business Wire|About: TAK
- cGMP Facility Builds Takeda’s Leadership Capabilities in Cell Therapy and Increases its Capacity to Supply Innovative Cell Therapies for Global Clinical Trials
- Five Collaborative Oncology Cell Therapy Programs Expected to be in Clinical Development by the End of FY2021
OSAKA, Japan--(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TKPHF) (TSE:4502/NYSE:TAK)
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200915005224/en/
For more information, visit https://www.takeda.com.
https://seekingalpha.com/symbol/TAK
Moderna builds footprint outside U.S. in Switzerland
Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies
Moderna builds footprint outside U.S. in Switzerland
Moderna Announces First Commercial Organization Outside North America in Switzerland
Wed September 16, 2020 5:00 AM|Business Wire|About: MRNA
Dan Staner appointed as Vice President and Managing Director, Switzerland
Reinforces Moderna’s commitment to Europe
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Moderna, Inc. (MRNA), (Nasdaq: MRNA)
To learn more, visit www.modernatx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005315/en/
https://seekingalpha.com/symbol/MRNA
Moderna builds footprint outside U.S. in Switzerland
https://seekingalpha.com/news/3614438-moderna-builds-footprint-outside-u-s-in-switzerland
Seattle Genetics teams up with Merck in cancer
SpringWorks teams up with Janssen in multiple myeloma study
Moderna builds footprint outside U.S. in Switzerland
Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations
Mon September 14, 2020 6:45 AM|Business Wire|About: MRK, SGEN
Companies to Co-Develop and Co-Commercialize Seattle Genetics’ Antibody-Drug Conjugate Ladiratuzumab Vedotin Globally; Merck (MRK) to Acquire $1 Billion Equity Stake in Seattle Genetics Common Stock
Companies Enter Exclusive License and Co-Development Agreement to Accelerate Global Reach of TUKYSA for HER2-Postive Cancers in Regions Outside the United States, Canada and Europe
Seattle Genetics (SGEN) to Host Conference Call Today at 9:00 a.m. ET
BOTHELL, Wash. & KENILWORTH, N.J.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq: SGEN) and Merck, known as MSD outside the United States and Canada, today announced two new strategic oncology collaborations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200914005237/en/
https://seekingalpha.com/symbol/MRK
https://seekingalpha.com/symbol/SGEN
Seattle Genetics teams up with Merck in cancer
https://seekingalpha.com/news/3613576-seattle-genetics-teams-up-merck-in-cancer
Seattle Genetics website at www.seattlegenetics.com
https://www.seattlegenetics.com/pipeline/tisotumab-vedotin
For more information, visit www.merck.com
For more information about our oncology clinical trials, visit www.merck.com/clinicaltrials.
SpringWorks teams up with Janssen in multiple myeloma study
SpringWorks teams up with Janssen in multiple myeloma study
SpringWorks teams up with Janssen in multiple myeloma study
SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
Mon September 14, 2020 6:30 AM|GlobeNewswire|About: SWTXGlobeNewswire
STAMFORD, Conn., Sept. 14, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (SWTX)
SpringWorks teams up with Janssen in multiple myeloma study
https://seekingalpha.com/news/3613550-springworks-teams-up-janssen-in-multiple-myeloma-study
https://seekingalpha.com/symbol/SWTX
https://seekingalpha.com/symbol/JNJ
For more information, please visit www.springworkstx.com
https://www.springworkstx.com/pipeline/nirogacestat/
SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
September 14, 2020 at 6:30 AM EDTPDF Version
Third collaboration to evaluate nirogacestat in combination with BCMA therapies across modalities
STAMFORD, Conn., Sept. 14, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX
Gilead nears deal to buy cancer drug maker for $20bn
SpringWorks teams up with Janssen in multiple myeloma study
SpringWorks teams up with Janssen in multiple myeloma study
Gilead nears $20B-plus deal to buy Immunomedics - WSJ
Sep. 12, 2020 3:31 PM ET|About: Gilead Sciences, Inc. (GILD)|By: Carl Surran, SA News Editor
Gilead Nears Deal to Buy Immunomedics for More Than $20 Billion
Biotech drugmaker has a market value of roughly $10 billion
By Cara Lombardo and Jonathan D. RockoffUpdated Sept. 12, 2020 3:31 pm ET
https://seekingalpha.com/symbol/GILD
Gilead to buy Immunomedics for $21B, bolstering its cancer arsenal
Sep. 13, 2020 4:32 PM ET|About: Gilead Sciences, Inc. (GILD)|By: Liz Kiesche, SA News Editor
https://seekingalpha.com/news/3613503-gilead-to-buy-immunomedics-for-21b-bolstering-cancer-arsenal
September 13, 2020
Gilead Sciences to Acquire Immunomedics
-- Gilead Adds TrodelvyTM, First-in-Class Antibody-Drug Conjugate Approved to Treat Triple-Negative Breast Cancer, With Promise in Other Forms of Breast Cancer and Additional Solid Tumors --
-- Acquisition Transforms Gilead’s Portfolio with First-in-Class Commercial Product with Significant Revenue and Best-in-Class Potential --
-- Trodelvy will Accelerate Gilead’s Emerging and Complementary Oncology Pipeline, Building on Agreements Executed Earlier This Year --
-- Immunomedics to Present Latest Clinical Findings on Trodelvy at European Society for Medical Oncology Virtual Congress 2020 This Coming Week --
FOSTER CITY, Calif. & MORRIS PLAINS, N.J.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Immunomedics (Nasdaq: IMMU)
AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
Fri September 4, 2020 7:00 AM|PR Newswire|About: ABBV, IMAB
I-Mab to receive upfront payment of USD180 million
Potential to explore combination therapies with I-Mab's lemzoparlimab and AbbVie's venetoclax (Venclexta®)
I-Mab to host call for investors on September 4 at 8:00 am ET
PR Newswire
NORTH CHICAGO, Illinois and SHANGHAI, China, Sept. 4, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) and I-Mab (IMAB)
For more information, please visit http://ir.i-mabbiopharma.com
For more information about AbbVie, please visit us at www.abbvie.com.
https://seekingalpha.com/symbol/IMAB
https://seekingalpha.com/symbol/ABBV
https://www.i-mabbiopharma.com/en/Pipeline.aspx
AbbVie and I-Mab Enter Into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
AbbVie and I-Mab to collaborate on development and commercialization of I-Mab’s highly differentiated anti-CD47 monoclonal antibody lemzoparlimab (TJC4)
I-Mab to receive upfront payment of USD180 million
Potential to explore combination therapies with I-Mab’s lemzoparlimab and AbbVie’s venetoclax (Venclexta®)
I-Mab to host call for investors on September 4 at 8:00am ET
NORTH CHICAGO, Illinois and SHANGHAI, China, September 4, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) and I-Mab (Nasdaq: IMAB)
https://www.i-mabbiopharma.com/en/article-564.aspx
ACE2-Fc is a recombinant protein
AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
iBio and Planet Biotechnology Enter into Exclusive Worldwide License Agreement for the Development of a COVID-19 Therapeutic
Fri August 28, 2020 7:15 AM|GlobeNewswire|About: IBIOGlobeNewswire
NEW YORK, Aug. 28, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (IBIO) (NYSE AMERICAN:IBIO) (“iBio” or the “Company”), a biotechnology innovator and biologics contract manufacturing organization, today announced that it has entered into an exclusive worldwide license agreement with Planet Biotechnology Inc. (“Planet”) for the development of Planet’s COVID-19 therapeutic candidate, ACE2-Fc.
https://www.ibioinc.com/therapeutics-and-vaccines/human-and-animal-health-internal-pipeline
https://www.planetbiotechnology.com/products.html
https://ir.ibioinc.com/press-releases/detail/134/ibio-and-planet-biotechnology-enter-into-exclusive
For more information, visit www.ibioinc.com.
https://seekingalpha.com/symbol/IBIO
AbbVie teams up with Harvard in viral infection research
AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy
AbbVie teams up with Harvard in viral infection research
August 25, 2020
AbbVie, Harvard University Form Research Alliance to Address Emergent Viral Diseases
NORTH CHICAGO, Ill. and CAMBRIDGE, Mass., Aug. 25, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Harvard University
AbbVie, Harvard University Form Research Alliance to Address Emergent Viral Diseases
Tue August 25, 2020 8:00 AM|PR Newswire|About: ABBV
NORTH CHICAGO, Ill. and CAMBRIDGE, Mass., Aug. 25, 2020 /PRNewswire/ -- AbbVie (ABBV) and Harvard University today announced a $30 million collaborative research alliance, launching a multi-pronged effort at Harvard Medical School (HMS)
For more information about AbbVie, please visit us at www.abbvie.com.
For more information, please visit https://otd.harvard.edu.
View original content:http://www.prnewswire.com/news-releases/abbvie-harvard-university-form-research-alliance-to-address-emergent-viral-diseases-301117726.html
AbbVie teams up with Harvard in viral infection research
Aug. 25, 2020 8:39 AM ET|About: AbbVie Inc. (ABBV)|By: Douglas W. House, SA News Editor
https://seekingalpha.com/news/3608508-abbvie-teams-up-harvard-in-viral-infection-research
https://seekingalpha.com/symbol/ABBV
Bristol-Myers Squibb to acquire protein engineer Forbius
Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration
AbbVie teams up with Harvard in viral infection research
Bristol Myers Squibb Enters Agreement to Acquire Forbius, Adding Lead TGF-beta Asset to Portfolio
Mon August 24, 2020 6:59 AM|Business Wire|About: BMY
Forbius’s Lead TGF-beta Asset, AVID200, is an Isoform-Selective TGF-beta Inhibitor, Currently in Phase 1 for Oncology and Fibrosis
NEW YORK & MONTREAL--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) and Forbius, a privately held, clinical-stage protein engineering company
View source version on businesswire.com: https://www.businesswire.com/news/home/20200824005159/en/
Bristol-Myers Squibb to acquire protein engineer Forbius
Aug. 24, 2020 7:12 AM ET|About: Bristol-Myers Squibb C... (BMY)|By: Douglas W. House, SA News Editor
https://seekingalpha.com/news/3608089-bristol-myers-squibb-to-acquire-protein-engineer-forbius
https://seekingalpha.com/symbol/BMY
Novel biologics
for treatment of
fibrosis & cancer
Merck finds London site for £1B research, business hub
Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration
Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration
Merck finds London site for £1B research, business hub
Aug. 18, 2020 3:52 AM ET|About: Merck & Co., Inc. (MRK)|By: Liz Kiesche, SA News Editor
Merck to build £1B London R&D hub for its first ex-U.S. early research center
by Ben Adams | Aug 18, 2020 4:23am
“We currently view the U.K. as a world leader in developing science, driven by the long-term emphasis on building a strong research and development infrastructure,” said David Peacock, MSD managing director for the U.K. and Ireland, speaking to the Financial Times.
Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration
Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration
Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration
Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration
Wed August 12, 2020 8:00 AM|Accesswire
RICHMOND HILL, ON / ACCESSWIRE / August 12, 2020 / Helix BioPharma Corp. (HBPC) (TSX:HBP)
Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration
Wednesday, August 12, 2020 8:00 AM
RICHMOND HILL, ON / ACCESSWIRE / August 12, 2020 / Helix BioPharma Corp. (TSX:HBP)
https://www.helixbiopharma.com/
https://www.helixbiopharma.com/pipeline/
https://seekingalpha.com/symbol/HBPCF
12 August 2020
Helix BioPharma Corp. and Moffitt Cancer Center Extend Immunotherapy Collaboration
RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP)
BiotechVortex™
Sarepta Therapeutics and University of Florida Announce Collaboration
Sarepta Therapeutics and University of Florida Announce Collaboration
Sarepta Therapeutics and University of Florida Announce Collaboration
Sarepta Therapeutics and University of Florida Announce Collaboration to Accelerate the Discovery and Development of Therapies for Rare Genetic Diseases
Tue August 11, 2020 8:30 AM|GlobeNewswire|About: SRPT
CAMBRIDGE, Mass. and GAINESVILLE, Fla., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics Inc. (SRPT), the leader in precision genetic medicine for rare diseases, and the University of Florida today announced a strategic collaboration to enable cutting-edge research for novel genetic medicines.
please visit www.sarepta.com
https://www.sarepta.com/products-pipeline
Zhongchao Inc. Renews Contract with Johnson & Johnson (China) Limited
Sarepta Therapeutics and University of Florida Announce Collaboration
Sarepta Therapeutics and University of Florida Announce Collaboration
Zhongchao Inc. Renews Contract with Johnson & Johnson (China) Limited, Extending the Cooperation since 2017
Tue August 4, 2020 7:12 AM|PR Newswire|About: ZCMD
SHANGHAI, Aug. 4, 2020 /PRNewswire/ -- Zhongchao Inc. (ZCMD)
More information about the Company can be found at its investor relations website at http://izcmd.com.
https://seekingalpha.com/symbol/ZCMD
https://seekingalpha.com/symbol/JNJ
Siemens Healthineers to Buy U.S. Varian Medical for $16 Billion Cash
Sarepta Therapeutics and University of Florida Announce Collaboration
BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab
DealsSiemens Healthineers to Buy U.S. Varian Medical for $16 Billion Cash
BUSINESS NEWSAUGUST 2, 2020 / 4:04 AM / UPDATED AN HOUR AGO
Siemens Healthineers expands into cancer care with $16.4 billion deal for Varian
4 MIN READ
MUNICH/BERLIN (Reuters)
Siemens Healthineers to Buy Varian Medical for $16.4 Billion
Deal will create a leader in the area of cancer therapy
By Tom FairlessUpdated Aug. 2, 2020 8:37 am ET
https://www.wsj.com/articles/siemens-healthineers-to-buy-varian-medical-for-16-4-billion-11596371354
https://seekingalpha.com/symbol/VAR
https://www.siemens-healthineers.com/en-us/
Siemens Healthineers Said to Near $15 Billion Purchase of Varian
Ed Hammond and Nabila Ahmed, Bloomberg News
Siemens Healthineers near $15B deal for Varian - Bloomberg
Aug. 1, 2020 9:24 PM ET|About: Siemens Healthineers AG (SEMHF)|By: Carl Surran, SA News Editor
https://seekingalpha.com/news/3598683-siemens-healthineers-near-15b-deal-for-varian-bloomberg
https://seekingalpha.com/symbol/SEMHF
BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab
BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab
BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab
BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab) Combination in Melanoma
Fri July 31, 2020 2:00 AM|GlobeNewswire|About: BNTX
- BioNTech (NTGN) and Regeneron plan to jointly conduct a randomized Phase 2 study combining BNT111 FixVac and Libtayo for the treatment of melanoma that has progressed after prior PD-1 blockade
- Combines two immunotherapies with complementary mechanisms of action with the aim to accelerate the path to market approval in melanoma if the trial is successful
- Development costs for the clinical trial to be shared equally with each company retaining full commercial rights to their respective product candidates
MAINZ, Germany, July 31, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced a strategic collaboration with Regeneron
For more information, please visit www.bioNTech.de
https://seekingalpha.com/symbol/BNTX
https://seekingalpha.com/symbol/REGN
clinical trial evaluating the combination of PD-1 inhibitor Libtayo (cemiplimab) and the latter's BNT111 FixVac candidate for the second-line treatment of patients with advanced cutaneous melanoma
Sangamo teams up with Novartis in neurodevelopmental disorders
BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab
Sangamo teams up with Novartis in neurodevelopmental disorders
Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders
Thu July 30, 2020 7:00 AM|Business Wire|About: SGMO
- Collaboration for gene regulation therapies for three neurodevelopmental targets, including for genes linked to autism spectrum disorder and intellectual disability
- Sangamo will receive a $75M upfront licensing fee and is eligible to receive up to $720M in potential milestones, as well as royalties on potential net commercial sales
BRISBANE, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (SGMO)
https://www.businesswire.com/news/home/20200730005166/en/
https://www.sangamo.com/pipeline
https://seekingalpha.com/symbol/SGMO
https://seekingalpha.com/symbol/NVS
https://seekingalpha.com/news/3597652-sangamo-teams-up-novartis-in-neurodevelopmental-disorders
Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders
July 30, 2020 at 7:00 AM EDTDownload PDF
- Collaboration for gene regulation therapies for three neurodevelopmental targets, including for genes linked to autism spectrum disorder and intellectual disability
- Sangamo will receive a $75M upfront licensing fee and is eligible to receive up to $720M in potential milestones, as well as royalties on potential net commercial sales
BRISBANE, Calif.--(BUSINESS WIRE)--Jul. 30, 2020-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO)
Elunate® (fruquintinib capsules)
BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab
Sangamo teams up with Novartis in neurodevelopmental disorders
Chi-Med and Lilly to Collaborate in Commercializing Elunate® in China
Tue July 28, 2020 2:00 AM|GlobeNewswire|About: HCM
HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (HCM) (“Chi-Med”) (Nasdaq/AIM: HCM) and Eli Lilly and Company
in June 2018 (clinicaltrials.gov identifier: NCT02314819).
(clinicaltrials.gov identifier: NCT03251378).
(clinicaltrials.gov identifier: NCT04322539).
please visit: www.chi-med.com.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701622/
Study of Elunate® (Fruquintinib) in Chinese Patients With Advanced CRC
https://clinicaltrials.gov/ct2/show/NCT04005066
https://seekingalpha.com/symbol/HCM
https://seekingalpha.com/symbol/LLY
Shineco proposes to acquire 73.7% interest in Changzhou Biowin Pharmaceutical
Ovid Therapeutics & University of Connecticut Enter into Strategic Research Collaboration
Shineco proposes to acquire 73.7% interest in Changzhou Biowin Pharmaceutical
Shineco, Inc. Enters into a Letter of Intent to Acquire Controlling Interest in Changzhou Biowin Pharmaceutical Co., Ltd
Published: Jul 27, 2020
BEIJING, July 27, 2020 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; Nasdaq: TYHT), a producer and distributor of Chinese herbal medicines, organic agricultural and hemp products, as well as various health and well-being-focused plant-based products
about Shineco, please visit http://tianyiluobuma.com.
For more information, please visit http://www.czbiowin.com/.
https://seekingalpha.com/symbol/TYHT
http://www.tianyiluobuma.com/index.php/English/Jishu/index.html
Astrazeneca inks $6B oncology deal with Daiichi Sankyo
Ovid Therapeutics & University of Connecticut Enter into Strategic Research Collaboration
Shineco proposes to acquire 73.7% interest in Changzhou Biowin Pharmaceutical
Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062
Mon July 27, 2020 2:00 AM|Business Wire|About: AZN, DSNKY
- Agreement represents second collaboration between Daiichi Sankyo (DSKYY) and AstraZeneca for a Daiichi Sankyo DXd antibody drug conjugate (ADC)
- AstraZeneca to pay Daiichi Sankyo up to $6 billion in total consideration, including a $1 billion upfront payment and up to an additional $5 billion contingent upon achievement of future regulatory and sales milestones
TOKYO, MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Daiichi Sankyo Company, Limited (DSKYF) (hereafter, Daiichi Sankyo)
https://www.businesswire.com/news/home/20200726005033/en/
For more information, please visit: www.DSCancerEnterprise.com.
please visit: www.daiichisankyo.com.
Astrazeneca inks $6B oncology deal with Daiichi Sankyo
Jul. 27, 2020 3:02 AM ET|About: AstraZeneca PLC (AZN)|By: Mamta Mayani, SA News Editor
https://seekingalpha.com/news/3595052-astrazeneca-inks-6b-oncology-deal-daiichi-sankyo
https://seekingalpha.com/symbol/DSKYF
https://seekingalpha.com/symbol/AZN
Ovid Therapeutics & University of Connecticut Enter into Strategic Research Collaboration
Ovid Therapeutics & University of Connecticut Enter into Strategic Research Collaboration
Ovid Therapeutics & University of Connecticut Enter into Strategic Research Collaboration
Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman Syndrome
Thu July 23, 2020 7:00 AM|GlobeNewswire|About: OVID
- Ovid to collaborate with renowned molecular geneticist and Angelman syndrome expert Stormy J. Chamberlain, Ph.D., to advance a short hairpin RNA (shRNA)-based therapeutic with the goal of addressing the underlying genetic cause of Angelman syndrome
- Ovid and UConn to collaborate on genetic therapy for potential future use alone or in combination with OV101, Ovid’s small molecule therapy for Angelman syndrome in Phase 3 development
NEW YORK and FARMINGTON, Conn., July 23, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (OVID)(NASDAQ: OVID)
https://seekingalpha.com/symbol/OVID
Bavarian Nordic and AdaptVac Sign Final License Agreement on COVID-19 Vaccine
Bavarian Nordic and AdaptVac Sign Final License Agreement on COVID-19 Vaccine
Ovid Therapeutics & University of Connecticut Enter into Strategic Research Collaboration
Bavarian Nordic and AdaptVac Sign Final License Agreement on COVID-19 Vaccine
Wed July 22, 2020 2:00 AM|GlobeNewswire|About: BVNRY
COPENHAGEN, Denmark, July 22, 2020 – Bavarian Nordic A/S (BVNKF)
For more information visit: www.AdaptVac.com.
For more information visit www.bavarian-nordic.com.
https://www.bavarian-nordic.com/
https://seekingalpha.com/symbol/BVNRY
https://www.adaptvac.com/pipeline
Gilead secures stake in cancer immunotherapy developer Tizona
Bavarian Nordic and AdaptVac Sign Final License Agreement on COVID-19 Vaccine
Gilead secures stake in cancer immunotherapy developer Tizona
Gilead Sciences Secures Exclusive Option to Acquire Tizona Therapeutics for $300 Million
Tue July 21, 2020 8:30 AM|Business Wire|About: GILD
– Gilead to Acquire 49.9% Equity Interest in Tizona –
– Gilead Will Have Right to Acquire Remainder of Tizona for up to $1.25 Billion in Potential Option Fees and Future Milestone Payments –
– Gilead Research and Development Funding to Accelerate Tizona’s First-in-Class Pipeline –
FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) today announced that it will invest $300 million to acquire a 49.9 percent equity interest in Tizona Therapeutics, Inc.
https://www.businesswire.com/news/home/20200721005336/en/
https://seekingalpha.com/symbol/GILD
Gilead secures stake in cancer immunotherapy developer Tizona
Jul. 21, 2020 8:42 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor
https://seekingalpha.com/news/3593056-gilead-secures-stake-in-cancer-immunotherapy-developer-tizona
Novocure teams up with Merck in lung cancer study
Bavarian Nordic and AdaptVac Sign Final License Agreement on COVID-19 Vaccine
Gilead secures stake in cancer immunotherapy developer Tizona
Novocure Announces Clinical Trial Collaboration with MSD to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer
Wed July 15, 2020 7:30 AM|Business Wire|About: NVCR
ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD (a tradename of Merck & Co., Inc.)
https://seekingalpha.com/symbol/NVCR
https://www.businesswire.com/news/home/20200715005430/en/
https://www.novocure.com/our-pipeline/
https://seekingalpha.com/symbol/MRK
https://www.merck.com/index.html
BiotechVortex™
Medtronic to Acquire Medicrea
MD Anderson & Sanofi announce strategic collaboration to accelerate oncology research & development
IQVIA and AstraZeneca Team-up to Support Development of Potential COVID-19 Vaccine
Medtronic to Acquire Medicrea
Wed July 15, 2020 2:30 AM|Business Wire|About: MDT, MRNTF, MRNTY
Medtronic will become the first company to offer an integrated solution including artificial intelligence-driven surgical planning, personalized spinal implants and robotic assisted surgery
DUBLIN & LYON, France--(BUSINESS WIRE)-- Medtronic plc (MDT), a global leader in medical technology, and Medicrea (MRNTF) (Euronext Growth Paris: FR0004178572 – ALMED Medicrea; OTCQX Best Market – MRNTF)
https://seekingalpha.com/symbol/MRNTY
https://seekingalpha.com/symbol/MRNTF
Medicrea’s product portfolio includes MEDICREA® UNiD® ASI (Adaptive Spine Intelligence) designed to support surgeon workflow in pre-operative planning and create personalized implant solutions for surgery.
https://www.medtronic.com/uk-en/index.html
https://seekingalpha.com/symbol/MDT
https://www.businesswire.com/news/home/20200714006115/en/
https://seekingalpha.com/symbol/MDT
IQVIA and AstraZeneca Team-up to Support Development of Potential COVID-19 Vaccine
MD Anderson & Sanofi announce strategic collaboration to accelerate oncology research & development
IQVIA and AstraZeneca Team-up to Support Development of Potential COVID-19 Vaccine
IQVIA and AstraZeneca Team-up to Support Development of Potential COVID-19 Vaccine
Tue July 14, 2020 8:00 AM|Business Wire|About: IQV
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- IQVIA™ (IQV) has announced its collaboration with AstraZeneca (LON: AZN) to accelerate development of a potential new vaccine for COVID-19. This joint initiative is part of the U.S. government’s recently announced Operation Warp Speed project.
https://www.businesswire.com/news/home/20200714005159/en/
https://seekingalpha.com/symbol/IQV
https://seekingalpha.com/symbol/AZN
MD Anderson & Sanofi announce strategic collaboration to accelerate oncology research & development
MD Anderson & Sanofi announce strategic collaboration to accelerate oncology research & development
MD Anderson & Sanofi announce strategic collaboration to accelerate oncology research & development
Sanofi and MD Anderson announce strategic collaboration to accelerate oncology research and development
Tue July 14, 2020 7:00 AM|PR Newswire|About: SNYPR Newswire
CAMBRIDGE, Mass. and HOUSTON, July 14, 2020 /PRNewswire/ -- Sanofi and The University of Texas MD Anderson Cancer Center
https://seekingalpha.com/symbol/SNY
Amgen Announces Additional Investment In BeiGene
Sinovac & Butantan Join to Advance Clinical Development of An Inactivated Vaccine for COVID-19
MD Anderson & Sanofi announce strategic collaboration to accelerate oncology research & development
Amgen Announces Additional Investment In BeiGene
Sun July 12, 2020 10:01 PM|PR Newswire|About: AMGN
THOUSAND OAKS, Calif., July 12, 2020 /PRNewswire/ -- Amgen (AMGN)
https://www.beigene.com/science-and-product-portfolio/pipeline
https://seekingalpha.com/symbol/AMGN
https://seekingalpha.com/symbol/BGNE
Sinovac & Butantan Join to Advance Clinical Development of An Inactivated Vaccine for COVID-19
Sinovac & Butantan Join to Advance Clinical Development of An Inactivated Vaccine for COVID-19
Sinovac & Butantan Join to Advance Clinical Development of An Inactivated Vaccine for COVID-19
Sinovac and Butantan Join Efforts to Advance the Clinical Development of An Inactivated Vaccine for COVID-19 to Phase III
Thu June 11, 2020 9:00 AM|Business Wire|About: SVA
BEIJING & SAO PAULO--(BUSINESS WIRE)-- Sinovac Biotech Ltd. (SVA), (“Sinovac” or the “Company”) (NASDAQ: SVA)
https://www.businesswire.com/news/home/20200611005491/en/
https://seekingalpha.com/symbol/SVA
https://seekingalpha.com/news/3582301-sinovac-inks-deal-to-advance-covidminus-19-vaccine
Lilly teams up with Evox Therapeutics in neurological disorders
Sinovac & Butantan Join to Advance Clinical Development of An Inactivated Vaccine for COVID-19
Sinovac & Butantan Join to Advance Clinical Development of An Inactivated Vaccine for COVID-19
Evox Therapeutics Announces a Multi-target RNAi and Antisense Research Collaboration and License Agreement With Lilly
Tue June 9, 2020 7:00 AM|PR NewswirePR Newswire
OXFORD, England, June 9, 2020 /PRNewswire/ -- Evox Therapeutics Ltd ('Evox' or the 'Company'), a leading exosome therapeutics company, is pleased to announce a research collaboration and license agreement with Eli Lilly and Company to leverage Evox's proprietary DeliverEX™ platform to develop and deliver RNA interference (RNAi) & antisense oligonucleotide (ASO) drug payloads for the potential treatment of neurological disorders
Lilly teams up with Evox Therapeutics in neurological disorders
Jun. 9, 2020 8:36 AM ET|About: Eli Lilly and Company (LLY)|By: Douglas W. House, SA News Editor
https://seekingalpha.com/news/3581471-lilly-teams-up-evox-therapeutics-in-neurological-disorders
https://www.evoxtherapeutics.com/
https://www.evoxtherapeutics.com/Pipeline
UbiVac Collaboration w/ Bristol Myers Squibb on Immunotherapy for Triple Negative Breast Cancer
UbiVac Collaboration w/ Bristol Myers Squibb on Immunotherapy for Triple Negative Breast Cancer
UbiVac Collaboration w/ Bristol Myers Squibb on Immunotherapy for Triple Negative Breast Cancer
Bristol Myers teams up with UbiVac in study of triplet therapy for breast cancer
Jun. 9, 2020 12:08 PM ET|About: Bristol-Myers Squibb C... (BMY)|By: Douglas W. House, SA News Editor
UbiVac is a clinical stage biotechnology company engaged in the research and development of therapeutic vaccines to combat cancer.
https://www.ubivac.com/technologies
https://seekingalpha.com/symbol/BMY
AbbVie and Genmab Announce Broad Oncology Collaboration
UbiVac Collaboration w/ Bristol Myers Squibb on Immunotherapy for Triple Negative Breast Cancer
UbiVac Collaboration w/ Bristol Myers Squibb on Immunotherapy for Triple Negative Breast Cancer
AbbVie and Genmab Announce Broad Oncology Collaboration
Wed June 10, 2020 6:00 AM|PR Newswire|About: ABBV, GMAB
- Companies establish a discovery research collaboration to create additional differentiated antibody therapeutics for cancer
- AbbVie to pay Genmab an upfront payment of USD 750 million with total potential milestone payments of up to USD 3.15 billion
PR Newswire
NORTH CHICAGO, Illinois and COPENHAGEN, Denmark, June 10, 2020 /PRNewswire/ -- AbbVie (ABBV) and Genmab A/S (GNMSF) (Nasdaq: GMAB)
https://seekingalpha.com/symbol/GMAB
https://www.genmab.com/product-pipeline
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® and DARZALEX FASPRO™ are trademarks of Janssen Pharmaceutica NV. TEPEZZA™ is a trademark of Horizon Therapeutics plc.
https://seekingalpha.com/symbol/ABBV
Sequencing by Expansion (SBX™)
UbiVac Collaboration w/ Bristol Myers Squibb on Immunotherapy for Triple Negative Breast Cancer
Regeneron & Colorado Center for Personalized Medicine Announce Human Genetics Research Collaboration
Roche acquires Stratos Genomics to further develop DNA based sequencing for diagnostic use
- Genomics insights generated through sequencing an individual's DNA play a critical role in personalised healthcare and clinical diagnostics of the future
- Roche is committed to developing a nanopore sequencer with the aim of providing the healthcare community and ultimately patients with faster and more accurate medical information to predict risk and detect disease
- This investment complements the development of Roche’s nanopore technology with the goal of an end-to-end sequencing solution starting from a patient sample to a diagnostic result
Basel, 22 May 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY)
Roche acquires nanopore sequencing developer Stratos Genomics
May 22, 2020 8:17 AM ET|About: Roche Holding Ltd ADR (RHHBY)|By: Douglas W. House, SA News Editor
https://seekingalpha.com/news/3577123-roche-acquires-nanopore-sequencing-developer-stratos-genomics
https://www.stratosgenomics.com/
Regeneron & Colorado Center for Personalized Medicine Announce Human Genetics Research Collaboration
Regeneron & Colorado Center for Personalized Medicine Announce Human Genetics Research Collaboration
Regeneron & Colorado Center for Personalized Medicine Announce Human Genetics Research Collaboration
Regeneron and Colorado Center for Personalized Medicine Announce Major New Human Genetics Research Collaboration
Mon May 11, 2020 7:00 AM|PR Newswire|About: REGN
TARRYTOWN, N.Y. and AURORA, Colo., May 11, 2020 /PRNewswire/ --
Regeneron Genetics Center will sequence 450,000 informed and consented patients
https://medschool.cuanschutz.edu/ccpm
https://seekingalpha.com/symbol/REGN
novel HSV-2 vaccine
Regeneron & Colorado Center for Personalized Medicine Announce Human Genetics Research Collaboration
Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases
Genocea Announces Material Transfer and License Option Agreement with Shionogi for Proprietary GEN-003 HSV-2 Antigens
Tue May 19, 2020 7:30 AM|GlobeNewswire|About: GNCA
CAMBRIDGE, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (GNCA) (NASDAQ: GNCA)
https://www.shionogi.com/us/en/
https://seekingalpha.com/symbol/SGIOY
https://seekingalpha.com/symbol/GNCA
Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases
Regeneron & Colorado Center for Personalized Medicine Announce Human Genetics Research Collaboration
Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases
Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases
Tue May 19, 2020 3:05 AM|PR Newswire|About: RHHBY
Vividion Receives $135 Million Upfront Payment With Potential for Multi-Billion Dollar Future Payments
PR Newswire
SAN DIEGO, May 19, 2020 /PRNewswire/ -- Vividion Therapeutics, a biotechnology
https://seekingalpha.com/symbol/RHHBY
https://vividion.com/wp-content/uploads/2020/05/Roche-Vividion-Press-Release_vFINAL.pdf
BiotechVortex™
Arrakis Therapeutics Enters Strategic Collaboration & License Agreement with Roche = RNA-Targeted
Arrakis Therapeutics Enters Strategic Collaboration & License Agreement with Roche = RNA-Targeted
Arrakis Therapeutics Enters Strategic Collaboration & License Agreement with Roche = RNA-Targeted
Roche teams up with Arrakis Therapeutics in RNA-targeted small molecules
Apr. 8, 2020 12:01 PM ET|About: Roche Holding Ltd ADR (RHHBY)|By: Douglas W. House, SA News Editor
https://seekingalpha.com/symbol/RHHBY
https://arrakistx.com/pipeline/
Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine
Arrakis Therapeutics Enters Strategic Collaboration & License Agreement with Roche = RNA-Targeted
Arrakis Therapeutics Enters Strategic Collaboration & License Agreement with Roche = RNA-Targeted
Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development
Thu April 9, 2020 7:50 AM|Business Wire|About: BNTX, PFE
- Pfizer (PFE) and BioNTech (BNTX) to jointly develop COVID-19 vaccine, initially in the United States and Europe, and scale-up manufacturing capacity to support global supply
- Potential to supply millions of vaccine doses by the end of 2020 subject to technical success of the development program and approval by regulatory authorities, and then rapidly scale up capacity to produce hundreds of millions of doses in 2021.
- BioNTech will contribute multiple mRNA vaccine candidates as part of its BNT162 COVID-19 vaccine program, which are expected to enter human testing in April 2020
- Pfizer will contribute its leading global vaccine clinical research and development, regulatory, manufacturing and distribution infrastructure and capabilities
- BioNTech will receive an upfront payment of $185 million, including an equity investment of approximately $113 million, and be eligible to receive future milestone payments of up to $563 million for a potential total consideration of $748 million
MAINZ, Germany & NEW YORK--(BUSINESS WIRE)-- BioNTech SE, and Pfizer Inc.
https://www.businesswire.com/news/home/20200409005405/en/
https://seekingalpha.com/news/3559589-pfizer-identifies-lead-covidminus-19-candidate
https://seekingalpha.com/symbol/BNTX
https://seekingalpha.com/symbol/PFE
Pfizer Identifies Lead Coronavirus Drug Candidate
Experimental medicine to be tested on patients this summer; arthritis therapy Xeljanz considered, too
By Jared S. Hopkins
Updated April 9, 2020 3:56 pm ET